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 This study determined the tissue-specific effect of adipose stem cells (ASC) 
within a melanoma environment for development of a cell-based melanoma therapy.  
Analysis included a subcutaneous B16-F1 melanoma model using thirty-one C57BL/6 
wild-type mice.  Melanoma xenografts were treated with cell-based therapies of CFDA-
SE-labeled human fibroblasts HF20x (control), non-differentiated ndASC or 
hematopoietic-differentiated HdASC.  No tumor regression was observed in presence of 
cell-based therapies, thus, the HdASC group demonstrated an increase in tumor growth 
accompanied with an up-regulated macrophage response, and increased angiogenesis.  In 
addition, this group demonstrated a decrease in Melan-A tumor marker and interferon-γ 
expression suggesting that ASC-supported tumor angiogenesis and macrophage immune 
response are accompanied with an inflammatory water influx and increased tumor 
porosity with no effect on tumor cell proliferation.  In addition, histology demonstrated 
CFDA-SE-labeled HF20x, ndASC, or HdASC inside tumors with no signs of cell death 
or apoptosis suggesting an immuno-suppressive effect of human ASC on the mouse 
immune system.      
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I.1. Molecular Mechanism of Cancer in General 
 Cancer is the second most common cause of death in the US, exceeded only by 
heart disease.  It is characterized by uncontrolled cellular growth caused by both external 
and internal factors (Figure 1) (American Cancer Society 2009).  The incidence of cancer 
occurs throughout the population at all age groups, thus, demonstrates ageing-dependent 
progression with varying outcomes depending on type and stage of cancer from complete 
remission to a fatal diagnosis (American Cancer Society 2009).  Besides benign cancers 
that reside in a contained localized stage and show slow growth expansion, malignant 
cancers with poor survival rates are often those associated with fast growth expansion 
and metastatic spread of tumor cells from the site of origin, accounting for as many as 
90% of all cancer deaths (Hanahan and Weinberg 2000; Bogenrieder and Herlyn 2003).   
 Besides the initial tumor cell origin that defines the primary spreading of the 
tumor, the surrounding tissue environment of a tumor contributes to the tumor 
malignancy.  In detail, the tumor environment is an intricate and complex system of many 
cell types, all of which can participate in progression of the tumor through the disruption 
of normal cell and tissue homeostasis (Albini and Sporn 2007).  Tumor cells have 
demonstrated the ability to adopt a variety of cellular phenotypes from their surroundings 
and produce a variety of cellular factors that support evasion of the host’s immune 
response (Sood, Seftor et al. 2001; Sood, Fletcher et al. 2002).  In addition, the tumor 
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Figure 1: Progression of Melanoma Through the Layers of the Skin. 
 Melanoma begins by the uncontrolled growth of melanocytes from an abnormal or 
irregular pigmented area of the skin that can be caused by both external and internal factors.  
The higher the invasiveness and proliferative properties of the tumor, the higher the risk of 
metastasis, and the lower the number of options available for treatment of the disease. 
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 tissue supports the degradation and remodeling of the tumor microenvironment and 
extracellular matrix (ECM) through secretion of proteolytic enzymes for promotion of 
tumor cell migration and invasion into the surrounding and nearby tissue (Chang and 
Werb 2001; Egeblad and Werb 2002).    
 Tumor angiogenesis is one of the important biological features related to tumor 
growth and tumor metastasis.  The switch from a normal cell to an angiogenic phenotype 
depends on the net balance between the amounts of positive and negative angiogenic 
factors released by the tumor (Ugurel, Rappl et al. 2001).  Recent data has indicated that 
carcinogenesis and tumor angiogenesis result from the interaction of cancer cells with 
various endothelial cells as well as interaction with the tumor tissue surrounding stromal 
cells and circulating inflammatory cells (Albini and Sporn 2007).  In detail, the normal 
recruitment of immune cells to the site of injury is obscured in presence of cancerous 
cells and triggers the release of pro-angiogenic factors for recruitment of endothelial 
precursor cells within the tumor area.  Thus, controlling the angiogenic properties of the 
tumor is an important strategy for the treatment and control of cancers as well as the 
progression to metastatic disease into the surrounding tissue (Folkman 1971; Carmeliet 
2005; Kerbel 2006).  
 
I.2. Incidence of Melanoma in Comparison to other Cancers 
 During the past decade, the incidence of melanoma has steadily increased within 
the United States, including approximately 68,720 newly diagnosed cases within the year 
2009 from a total cancer incidence of more than one-million reported cases (Enk, Becker 
et al. 2006; Tawbi and Nimmagadda 2009).  Compared to other skin tumors, melanoma is 
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characterized as a more aggressive tumor type due to a higher tendency to metastasize to 
other parts of the body.  Concurrently, widespread metastasis is the main cause of death 
in melanoma patients and is seen in about 20% of all melanoma cases (Zbytek, Carlson et 
al. 2008).   
 If detected early, melanoma has a good prognosis and survival rate for a healthy 
patient outcome.  The treatment course for melanoma in its early stages is predominantly 
surgical, consisting of the excision of the primary tumor (Zbytek, Carlson et al. 2008).  
After surgical removal of the primary tumor, potential metastasis of any residual non-
detected melanoma cells can cause a remaining medical risk (Ugurel, Rappl et al. 2001).  
In order to prevent metastasis and improve patient survival rates, numerous therapeutic 
strategies have been tested in recent years, with the majority being based on immunologic 
approaches (Enk, Becker et al. 2006).  Since metastasis develops within a local, or 
systemical immune system, the goal of immunotherapeutic strategies is to improve the 
host immune response by achieving and maintaining an anti-tumor response by also 
maintaining the general health of the patient (Enk, Becker et al. 2006).   
 
I.3. Molecular Mechanisms of Melanoma Development  
 Melanocytes that normally possess limited proliferative potential comprise 
approximately 1-2% of epidermal cells and reside in the basal layer of the epidermis 
where they provide the neighboring keratinocytes with the protective pigment melanin. 
The formation of malignant melanoma from skin melanocytes is promoted by up-
regulation of melanin production during epidermal injury through incidents such as 
ageing, photoageing, thermal burns, harsh chemicals and mechanical trauma or other 
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stimuli. Thus, the complex pathogenic molecular mechanism underlying melanoma 
development is relatively unknown and include genetic, metabolic, and molecular 
alterations within melanoma tissue forming melanocytes all of which can be caused by a 
combination of both internal and external factors (Palmieri, Capone et al. 2009).  For 
instance, the enhanced melanogenesis and proliferation of melanocytes can result directly 
from DNA damage or indirectly from surrounding keratinocytes and invading 
macrophages released inflammatory mediators (Gilchrest and Eller 1999; Yaar and 
Gilchrest 2001).  For instance, overproduction of interleukin 8 (IL-8) by melanoma 
residing melanocytes has been demonstrated in the majority of cutaneous melanoma 
where it stimulates cell migration, proliferation and metastasis (Luca, Huang et al. 1997; 
Nurnberg, Tobias et al. 1999; Ugurel, Rappl et al. 2001).  In addition, proliferation 
inhibitory growth factors such as TFN-α, TGF-β and cytokines IFN-α, IFN-γ, interleukins 
IL-2, IL-12, and IL-6 have been found to be altered in presence of melanoma 
development (Zbytek, Carlson et al. 2008).  Especially metastatic melanomas 
demonstrate resistance to these immunosuppressive growth factors and cytokines through 
modification of cytokine receptors (Frohlich, Schlagenhauff et al. 2001; Seftor, Seftor et 
al. 2001; Enk, Becker et al. 2006; Quintanilla-Dieck, Codriansky et al. 2008; Zbytek, 
Carlson et al. 2008).  For instance, TGF-β represents one important immuno-suppressive 
growth factor that plays a role in the progression of tumor formation and its 
overproduction has been found in the majority of melanoma tumors.  In detail, TGF-β 
negatively impacts synthesis of interleukin-3 (IL-3) and granulocyte macrophage colony-
stimulating factor (GM-CSF) that are important for recruitment of T-lymphocytes, 
granulocytes and monocytes from the bone marrow for phagocytosis and cytotoxic 
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degradation of tumor cells (Enk, Becker et al. 2006).  In addition, the production 
metalloproteases can be altered within melanoma tissue thereby supporting reconstitution 
of the ECM by allowing growth and metastic spread of the tumor into nearby tissues 
(Frohlich, Schlagenhauff et al. 2001; Seftor, Seftor et al. 2001; Enk, Becker et al. 2006; 
Quintanilla-Dieck, Codriansky et al. 2008; Zbytek, Carlson et al. 2008).  In addition, 
growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast 
growth factor (bFGF) promote tumor growth by supporting angiogenesis, anchorage 
independent growth and metastatic capacity of primary invasive melanomas (Reed, 
McNutt et al. 1994; Graeven, Fiedler et al. 1999).   
 
I.4. Role of Mesenchymal Stem Cells in Anti-Cancer Therapy 
 In comparison to embryonic stem cells that regulate embryogenesis, mesenchymal 
stem cells (MSC) are pluri-potent regenerative cells capable of self-renewal and 
differentiation into more specialized cells within the adult human body.  The regenerative 
characteristics of mesenchymal stem cells to differentiate in vitro and in vivo along 
multiple cellular lineages and their immunosuppressive characteristics make MSC a new 
promising tool for the delivery of therapeutic agents for cell, gene, and anti-cancer 
therapy (Figure 2) (Pittenger, Mackay et al. 1999; Gimble and Guilak 2003; 
Sotiropoulou, Perez et al. 2006; Ozawa, Sato et al. 2008).  In contrast to many biologic 
agents for cancer therapy that are limited by their short half-life or excessive toxicity to a 
particular area, the use of MSC supported cell-based therapy through targeted tumor site 
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Figure 2: The Hematopoietic Differentiation Potential of Mesenchymal Stem Cells 
(MSC). 
 Mesenchymal stem cells (MSC) have the potential to differentiate into several cellular 
lineages based on the types of cytokines, growth factors, or a combination of both used 
throughout the differentiation process.  Hematopoietic differentiation of MSC can give rise to 
all the blood cell types from myeloid (monocytes, macrophages, neutrophils, basophils, 
eosinophils, erythrocytes, megakaryocytes/platelets, and dendritic cells), and lymphoid 
lineages (T-cells, B-cells, Plasma cells, and NK-cells) that all participate in the immune 
response.  The types of cytokines and factors produced by these cells not only benefit the 
immune response, but can also be used in tumor cell defense. 
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 injection represents a means to deliver anti-cancer therapy for an extended time period 
directly at the site of the tumor (Studeny, Marini et al. 2004).  Further advantages of 
MSC-based anti-cancer therapy are based on their regenerative potential.  
Correspondingly, the resemblance of the tumor microenvironment with an injured or 
unhealed tissue has been previously demonstrated to attract circulating MSC for 
assistance in tissue repair mechanisms (Dvorak 1986; Studeny, Marini et al. 2002; 
Studeny, Marini et al. 2004; Hakkarainen, Sarkioja et al. 2007).  For instance, an in vivo 
analysis by Ozawa, Sato et al, showed a significant accumulation of MSC at the site of 
tumors, which may suggest that MSC could be utilized to target tumors and may have the 
potential for local delivery of anti-cancer molecules locally in a concentrated and specific 
fashion (Hakkarainen, Sarkioja et al. 2007; Ozawa, Sato et al. 2008).   
 The therapeutic potential of these tumor tracking or homing properties of MSC 
has been demonstrated in recent studies that used modified MSC for anti-cancer therapy 
of murine glioma, melanoma, and ovarian and breast cancer models (Hakkarainen, 
Sarkioja et al. 2007).  For instance, one model that used Herpes simplex virus (HSV) 
thymidine kinase producing bone marrow-derived stem cells (BSC) in tumor-bearing 
nude mice demonstrated an efficient tumor regression by HSV-dependent cell lysis 
(Ozawa, Sato et al. 2008).  In addition, several other studies have analyzed MSC as 
vehicles for the delivery of growth inhibitory cytokines to inhibit tumor or cancer cell 
proliferation.  In detail, one study that used cell-based therapy of IL-12 cytokine 
producing BSC demonstrated a pronounced retardation of subcutaneous melanoma tumor 
growth in mice with prolonged survival that was comparable to direct IL-12 cytokine 
therapy (Elzaouk, Moelling et al. 2006).  Another study found pronounced reduction of 
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human melanoma treated with human BSC expressing interferon (IFN)-β in a xenogenic 
mouse model (Elzaouk, Moelling et al. 2006).  A similar study that was based on BSC 
delivery of IFN-β found suppression of pulmonary metastases, presumably through the 
local production of IFN-β in the tumor microenvironment (Studeny, Marini et al. 2004).  
In conclusion, these studies support MSC as an effective tool for the targeted delivery of 
therapeutic proteins or agents to cancer sites.     
 
I.5. Role of Adipose Tissue-Derived Stem Cells in Anti-Cancer Therapy 
 Adipose tissue represents an abundant, easily accessible, and replenishing source 
of adult mesenchymal stem cells that can be harvested through minor invasive liposuction 
surgery (Gimble and Guilak 2003; Kucerova, Altanerova et al. 2007; Schaffler and 
Buchler 2007; Zhu, Liu et al. 2008; Locke, Windsor et al. 2009).  Correspondingly, 
adipose tissue represents a safe autologous source of stem cells the can be used for 
personalized cell-based therapies with minimal risk to the donor and no ethical concerns 
for use in a clinical setting (Kucerova, Altanerova et al. 2007).   
 Compared to other MSC derived from other sources, e.g., bone marrow-derived 
stem cells, adipose tissue-derived stem cells have an equal potential to differentiate into 
several types of cells and tissues of mesodermal origin (Figure 3) (Gimble and Guilak 
2003; Schaffler and Buchler 2007).  Comparable to bone marrow-derived stem cells, 
ASC have an equal ability of self-renewal and differentiation along multiple cellular 
lineages (Figure 2) (Strem, Hicok et al. 2005).  In contrast to other MSC, ASC have the 
advantage to grow more rapidly in culture, exhibit stable growth and proliferation 
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Figure 3: Differentiation Potential of Adipose Stem Cells (ASC). 
 Adipose stem cells (ASC) have the ability to differentiate toward several different 
cellular lineages.  The differentiation process depends on exposure to a selected combination 
of growth factors and the provided growth matrix in order to achieve the desired cellular 




 kinetics, can differentiate into similar cell types and their good cryo-preservation make 
them ideal tools for therapeutic intervention in cell-based therapies, and clinical uses 
(Kern, Eichler et al. 2006; Locke, Windsor et al. 2009).  Also, the lack of immunogenic 
marker expression, e.g., human leukocyte antigen (HLA-DR), and the corresponding 
immunosuppressive properties of ASCs make these cells also suitable for allogenic 
transplantation procedures by decreasing the risk of tissue rejection (Kucerova, 
Altanerova et al. 2007; Schaffler and Buchler 2007).  The hematopoietic potential of 
ASC was recently demonstrated in a study conducted by Minana, et al. 2008, that 
demonstrated CD45 positive cells within the adherent ASC population representing a 
macrophage/monocyte population and were able to differentiation a CD45 negative and 
CD105 positive non-adherent ASC subset into hematopoietic cells that did not express 
CD31 and included both, CD34 negative and CD34 positive cells (Minana, Carbonell-
Uberos et al. 2008).  These cells were further able to differentiate into CD34 positive 
erythrocytic precursors and dendritic cell precursors that were CD14 positive and CD34 
negative.  Another study conducted by Corre, Barreau et al. 2006, showed that ASC are 
able to support complete differentiation into hematopoietic progenitor cells, but were 
unable to maintain the survival and self-renewal of normal hematopoietic stem cells 
(Corre, Barreau et al. 2006).  Correspondingly, the generation of HdASC cell-based 
therapy might be beneficial as a combination therapy with another drug-based anti-cancer 
therapy to boost the host immune system for tumor recognition and elimination.  Thus, 
the detailed mechanism of action regarding key molecules for differentiation, 
immunosupression, and hematopoietic differentiation of HdASC and their effect on 
tumor regression remains to be determined.   
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II. HYPOTHESIS AND SPECIFIC AIMS 
 
II.1. Rationale 
 Through overproduction of immunosuppressive and inflammatory cytokines, such 
as TGF-β and interleukins (IL) e.g., IL-8, tumor cells are capable to escape recognition 
and potentiate cell migration, proliferation and metastasis in the majority of cutaneous 
melanoma (Luca, Huang et al. 1997; Nurnberg, Tobias et al. 1999; Ugurel, Rappl et al. 
2001).  In detail, TGF-β lowers the production of IL-3 and granulocyte macrophage 
colony-stimulating factor (GM-CSF) for the recruitment of T-lymphocytes, granulocytes 
and monocytes for phagocytic and cytotoxic degradation of tumor cells (Enk, Becker et 
al. 2006).  Consequently, the direct introduction of immunocompetent hematopoietic 
cells through targeted tumor site injection represents a means to eliminate potential 
immunosuppressive tumor escape mechanisms.  Recently, adipose tissue-derived 
mesenchymal stem cells (ASC) have become of major interest due to their similarity with 
other mesenchymal stem cells (MSC), regarding anticancer tropism and their ability to 
differentiate into multilineages including adipogenic, osteogenic, chondrogenic and 
hematopoietic cells (Strem, Hicok et al. 2005; Corre, Barreau et al. 2006; Kern, Eichler et 
al. 2006; Kucerova, Altanerova et al. 2007; Minana, Carbolell-Uberos et al. 2008).  The 
homing of MSCs to specific tumor target tissue has been demonstrated previously in e.g., 
glioblastoma, Kaposi’s sarcoma, ovarian cancer and lung melanoma metastases 
(Nakamura, Ito et al. 2004; Studeny, Marini et al. 2004; Khakoo, Pati et al. 2006).  
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Within the target tissue, MSCs have been observed to inhibit tumor growth in different 
types of animal models.  For instance, Maestroni et al. demonstrated that co-injection of 
mouse bone marrow derived mesenchymal stem cells (BSC) together with Lewis lung 
carcinoma or B16-F1 melanoma cells results in inhibition of tumor growth, thus, the 
factors mediating the antitumor activity remain to be determined (Maestroni, Hertens et 
al. 1999).  Another study by Ohlsson et al. suggested that infiltration of monocytes and 
granulocytes might be the reason for BSCs-dependent antiproliferative action on colon 
carcinoma (Ohlsson, Varas et al. 2003).  The active recruitment of hematopoietic cells by 
MSC is further supported by the MSC observed secretion of immunogenic cytokines such 
as IL-6, stem cell factor (SCF) and GM-CSF (Majumdar, Thiede et al. 2000; Wang, Liu 
et al. 2003).  In comparison to bone marrow-derived MSC that have been extensively 
studied, the effect of ASCs on tumor regression remains to be determined.  According to 
the existing similarities between bone marrow-derived MSC and ASC regarding 
immunologic cytotoxicity and tumor tracking properties, the targeted injection of ASC 
into a melanoma tissue environment represents a novel melanoma anti-cancer therapy 
approach.  
 
II.2. Significance of Study 
 The development of novel strategies that use the tumor tracking properties of 
ASC might represent a beneficial therapy for cancers that are unresponsive to hormonal 
agents or have developed drug resistance.  The anticancer effect of ASC is thought to 
reduce tumorigenic hyperproliferation, increase apoptotic signaling and immunogenic 
responses through potential ASC differentiation into immunogenic cells.  The easy high 
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yield purification of ASC from liposuction aspirates and the potential use of these adult 
stem cells as an autologous source with no ethical concerns make them ideal for long-
term therapy in allogeneic or xenogeneic recipients (Bartholomew, Sturgeon et al. 2002; 
Elzaouk, Moelling et al. 2006; Sotiropoulou, Perez et al. 2006).  Expected benefits for the 
patient are potential stem cell-assisted targeting of anticancer therapeutics to remote 
melanoma areas especially those that remain unrecognizable by current screening 
methods. 
 
II.3. Hypothesis and Specific Aims 
Overall Hypothesis:  
 The hypothesis is that differentiation of ASC into immuno-competent 
hematopoietic cell lineages can cause an enhanced immune cell and cytokine based anti-
tumor response within a melanoma environment, or against the melanoma cells that can 
be used as an anti-cancer therapy.  
Specific Aims:  
1) To test the hypothesis that ASC promote melanoma regression through 
differentiation into immunocompetent hematopoietic cell lineages. 
 
2) To test the hypothesis that ASC promote melanoma regression through alteration 
of melanoma-related cytokine and mitogenic responses. 
 
 This study analyzes the role of ASC in promotion of tumor regression within a 
melanoma environment.  Analysis will include subcutaneous implantation of B16-F1 
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melanoma xenografts into C57BL/6J wild-type mice.  Established proportional 3mm 
diameter melanoma tumors will be treated using cell-based therapies of human fibroblasts 
(HF20x, control), non-differentiated (ndASC) or hematopoietic lineage-differentiated 
(HdASC) for a four-day time period.  Subsequently, the tissue-specific effect of the 
mouse melanoma environment on ndASC and HdASC and their immunologic response 
against tumor cells will be assessed using tumor area and weight measurements, 
immunoblotting, immunohistochemistry, flow-cytometry and ELISA analysis. 
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III. MATERIALS AND METHODS 
 
III.1. Cells and Cell Culture  
 The non-differentiated human adipose stem cells (ndASC) used in this experiment 
were purchased from Invitrogen (StemPro® Human Adipose-Derived Stem Cells, 
cat#R7788-110, Lot#1199; Invitrogen, Corporation, Carlsbad, CA). B16-F1 mouse 
melanoma cells and human fibroblasts HF20x were purchased from ATCC (B16-F1: 
mouse (mus musculus) cat#CRL-6323, Lot#3995448; HF20x: cat#PCS-201-010 FZ, 
lot#58243223, dermal fibroblasts, normal, human, neonatal foreskin; ATCC, Manassas, 
VA).  The cell line B16-F1 was additionally tested for microbial contamination by MU 
Research Animal Diagnostic Laboratory, Columbia, MO.  B16-F1 Mouse Melanoma 
cells and HF20x cells were grown in Dulbecco’s Modified Medium (DMEM, Cellgro®, 
Mediatech, Inc. Herndon, VA) supplemented with 10% fetal bovine serum (FBS), 4.5 g/l 
glucose and L-glutamine/ sodium pyruvate, and 1x Antibiotic-Antimycotic Solution 
(final concentration of 100 U. Penicillin, 100 µg/mL Streptomycin, 0.25 µg/mL 
Amphotericin B).  The ndASCs were grown in Hyclone AdvanceSTEMTM Mesenchymal 
Stem Cell Expansion Kit containing Hyclone AdvanceSTEMTM Basal Medium for 
Undifferentiated Mesenchymal Stem Cells with according growth supplement (Thermo 
Scientific) that was further supplemented with1x Antibiotic-Antimycotic Solution.  B16-
F1 Mouse Melanoma cells, HF20x cells, and the HdASCs were cultured in a 37oC 
incubator with 20% O2 and CO2, while the ndASCs were cultured in a 37oC incubator 
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with 5% O2 and CO2.  To avoid passage-related phenotypic changes, cells were used 
from passages three to seven. 
 
III.2. In Vitro Co-Culture Experiment 
B16-F1 melanoma cells at a concentration of 1x105 cells/well were either cultured 
directly on the bottom of a 12-well plate or on top of coverslips contained in a 12-well 
plate.  The HF1, ndASC, and HdASC cell groups were labeled with fluorescent dye 
Vybrant® CFDA-SE Cell Tracer Kit (InvitrogenTM) and added on top of the B16-F1 
melanoma cells at a concentration 1x105 cells/well one hour after the B16-F1 cells had 
attached.  After 24 hours in culture, the co-cultures were analyzed by live-microscopy or 
fixed for immunocytochemical analysis.  Analysis of the live cell cultures was done using 
the phase-contrast setting on the Motic AE Inverted Microscope with an Infinity2 camera 
system.  
 
III.3. In Vitro Testing of Co-Culture Supernatant  
 B16-F1 cells were plated at 1x105 cells/well followed by addition of regular 
culture medium (DMEM plus supplements) or addition of culture supernatants taken 
from three-day HF1, ndASC, and HdASC culture that were previously filtered using 0.2 
micron sterile filters.  Following 24 hours, cultures were analyzed by live-microscopy 
using the phase-contrast setting on the Motic AE Inverted Microscope with an Infinity2 




III.4. Alamar Blue® Proliferation Assay (Biosource) 
 B16-F1, HF1, ndASC, and HdASC were grown in 12-well plates and in the last 
hour of the experiment, the medium in each of the 12-well plates was supplemented with 
70µl Alamar Blue® reagent/ml culture medium.  Following a one-hour incubation, the 
emission at 620nm was recorded using a FusionTM Microplate Analyzer (Packard). 
 
III.5. Hematopoietic Differentiation of ndASC into HdASC  
 Prior to differentiation, the ndASC were transferred from a 37oC incubator with 
5% O2 and 5% CO2 to the 37oC incubator with 20% O2 and 5% CO2.  Differentiation of 
ndASC into HdASC was done in DMEM containing 12.5% Fetal Bovine Serum (FBS), 
1x Antibiotic-Antimycotic Solution, 2-Mercaptoethanol (5x10-5M), and Human SCF 
(50ng/ml), GM-CSF (10ng/ml) IL-3 (10ng/ml) (R&D Systems) for 9 days in culture. 
 
III.6. Vybrant®  CFDA-SE Cell Tracer Kit (Molecular Probes) 
  Preparation of the CFDA-SE staining solution was prepared accordingly to the 
manufacturer’s protocol.  In brief, the desired 10 µM of working solution of CFDA-SE 
used for this melanoma experiment was prepared by dissolving component A with 90 µL 
of component B (DMSO) from the Vybrant® CFDA-SE Cell Tracer Kit, and then adding 
15 µL of this stock solution to 15 mL (1:1000 dilution) of PBS.  This working solution of 
CFDA-SE was then added to the cells followed by a 15 minute incubation at 37ºC.  After 
the 15 minute incubation time, the CFDA-SE dye solution was replaced with cell culture 
specific medium.  After the proper amount of time, cells were then taken up in 
physiological saline solution for use in the animal experiment. 
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III.7. Cell Culture and CFDA-SE Staining of HdASC, ndASC, and HF20x Cells for 
the Animal Study   
 All cells for use in the animal experiment (B16-F1melanoma cells, ndASCs, and 
HF20x cells) were thawed from frozen 1mL cell suspension aliquots in liquid nitrogen.  
The cells were plated into the corresponding culture media twenty-one days prior to the 
start of the animal experiment in order to achieve the necessary cell numbers 
(approximately 1x106 cells/200 µL per animal) for each cell-therapy group.  At 85-90% 
confluency, cells were split into new cell flasks for continued growth. B16-F1 melanoma 
cells were used directly in the experiment without any additional staining.  The HF20x 
and ndASCs were stained with CFDA-SE two days prior to injection.  The ndASC cells 
intended for hematopoietic cell differentiation (HdASCs) were stained with CFDA-SE 
one day prior to hematopoietic differentiation followed by 9 days in hematopoietic 
culture medium before use in experiment.   
 
III.8. Cell Culture Harvest and Counting of Cells for Animal Study   
 For cell harvest of B16-F1, HF20x, and ndASCs the cell culture media from each 
of the flasks was removed, cells were washed in 1x PBS followed by trypsinization in 
Trypsin EDTA and uptake of cells in cell culture media.  For hematopoietic differentiated 
cells, higher differentiated detached cells were collected before trypsinization of attached 
progenitor cells from the bottom of the cell culture flask.  Following determination of cell 
numbers using a hemocytometer, cell suspensions were centrifuged at 1000xg for 5 
minutes and medium was replaced with 0.9 % normal saline to adjust the cell 
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concentration to approximately 1x106 cells/200 µL injection.  Around 200 µL cellular 
aliquots from each of the cellular groups were then taken up by 1 ml 255/8 gauge syringes 
for injection into the tumor areas on the mice.  
 
III.9. Animal Experiment 
 A total of n=31 ten week old male C57BL/6 mice (Harlan Laboratories, Inc. 
Indianapolis, IN) were housed in the Laboratory Animal Research (LAR) facility at 
Wright State University (WSU) under the institutional animal protocol number AUP740 
and bio-safety protocol numbers IBC123 and IBC194.  All mice were kept in a controlled 
environment for the duration of the study and were provided with adequate food and 
water throughout.  To ensure healthy weight gain, mice were weighed at the day of 
arrival and one week after arrival at the LAR facility.  In addition, mice were weighed the 
day prior to B16-F1 melanoma injections followed by daily weight determination until 
the end of the study.   
 Before the start of the experiment, all mice were anesthetized under inhaled 
isofluorane (2% isofluorane in 98% oxygen) followed by shaving of their right hind 
flanks, and subcutaneous injection of right thighs with 200 µL 5x106 cells/ml B16-F1 
mouse melanoma cells using a 1 mL 255/8 gauge syringe.  After each injection, mice were 
marked with a permanent marker at the injection site of the B16-F1 melanoma cells, to 
help locate initial tumor growth.  The animals were then randomly divided into a control 
group a) of ten (n=10) animals that received 200 µL approximately 5x106 cells/ml 
CFDA-SE labeled HF20x human fibroblast cells, and experimental groups of b) ten 
(n=10) animals that received 200 µL 5x106 cells/ml CFDA-SE labeled human non-
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differentiated adipocyte-tissue derived stem cells (ndADSC) or c) 200 µL of 5x106 
cells/ml CFDA-SE labeled hematopoietic differentiated human adipocyte-tissue derived 
stem cells (HdADSC) by injection.  On the day of cell-based therapy, mice were 
anesthetized under inhaled isofluorane before injection of the corresponding treatment 
into the center of the established tumor by using 1 mL 255/8 gauge syringes.  Tumor 
growth was monitored and measured every second day (from day of B16-F1 melanoma 
injections) using a digital caliper by measuring in two perpendicular dimensions to 
determine the tumor area extension according to the formula length x width.  Four days 
after HF20x, ndASC and HdASC implantation, animals were sacrificed after loss of 
consciousness in a CO2 chamber by administering a lethal dose of carbon dioxide 
(initially 70% then increased to 100%), and checking of mouse vital signs for cessation of 
heartbeat, respiration, and toe-pinch reflexes.  Inferior vena cava blood was collected 
from each mouse using a 1 ml 255/8 gauge syringe directly after euthanasia followed by 
tumor excision, and tumor weight determination.  Groups b) HF20x (n=10), c) ndASC 
(n=10) and d) HdASC (n=10) were subdivided into two subgroups of 1) (n=6) animals 
for immunohistochemical analysis and 2) (n=4) animals for immunoblotting and ELISA 
analysis that included further partitioning of (n=2) tumors from each group for flow 
cytometry analysis.  Tumor samples were labeled and stored in a -80oC freezer until 
needed for analysis.   
 
III.10. Tumor Growth and Weight Measurements 
 Tumor growth was monitored and measured every second day (from day of B16-
F1 melanoma injections) using a digital caliper measuring in two perpendicular 
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dimensions to determine the tumor area extension according to the formula: area (mm2) = 
length (mm) x width (mm).  In addition, the percent tumor area increase was determined 
by the following formula:   
 Tumor area (%) =   (area day of interest[mm2]) - (area day 0[mm2])  *100 
             (area day 0[mm2])   
In addition, tumor weights (g) were determined at the time of tumor excision.  
 
III.11. Blood Plasma Preparation 
 The collected inferior vena cava blood was placed in a 4 mL BD® vaccutainer 
blood tube coated with K2EDTA (7.2 mg) and placed on ice for storage.  Blood tubes 
were spun at 1000xg for blood plasma collection.  Blood plasma samples were placed in 
1mL eppendorf tubes and stored in a -80oC freezer until use for ELISA analysis. 
 
III.12. Protein Extraction 
 Cellular proteins of the tumor were extracted according to the T-PER® Tissue 
Protein Extraction Reagent (Pierce, Thermo Scientific) manufacturers procedure.  In 
brief, approximately 1 gram (g) of tissue was lysed with 20 mL of T-PER® Reagent.  
Tumors were further lysed using a sonicator (Sonic Dismembrator, Fisher Scientific) at a 
continuous setting of 3 until the tumor tissue appeared to be completely homogenized. 
Following centrifugation at 10,000xg for 5 minutes, the supernatant containing the 
cellular proteins was collected.  Protein concentrations of the cellular extracts from the 
tumors were determined using the Bradford method (Bradford 1976).  After total protein 
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determination, the total protein concentration of all samples was adjusted to 0.45 µg/ml 
for use in ELISA and Western Blot analysis. 
 
III.13. Enzyme-Linked Immunosorbent Assay (ELISA) Analysis 
 ELISA analysis for cytokines IFN-γ (Mouse IFN-γ Immunoassay) and TGF-β 
(Mouse/Rat/Porcine/Canine TGF-β1 Immunoassay) were prepared according to the 
Quantikine® (R&D Systems, Minneapolis, MN) manufacturer’s user manual.  In brief, the 
ELISA is based on monoclonal primary antibodies, which are specific for mouse IFN-γ 
and TGF-β.  The addition of the tumor and plasma samples to the ELISA plate will result 
in binding of either existing IFN-γ, or TGF-β to the corresponding matrix-bound 
antibodies.  Following the protocol provided by the kit, both IFN-γ and TGF-β were 
detected by addition of polyclonal primary antibodies for both IFN-γ and TGF-β coupled 
to horseradish peroxidase for conversion of tetra-methly-benzidine into a colorimetric 
product.  For the IFN-γ ELISA plate, tumor tissue samples were analyzed in triplicates, 
and the plasma samples in duplicates.  For the TGF-β ELISA plate, the tumor tissue 
samples and plasma samples were analyzed in triplicates.  The absorbance of the samples 
from each ELISA plate was determined at 450 nm detection wavelength using a 
SPECTRAmax Plus micro-plate reader supported with the SOFTmax Pro software. 
 
III.14. SDS-PAGE and Western Blot Analysis  
 Tumor protein extracts (0.45 µg/ml) were separated on 7.5%, 10%, or 15% 
Sodium dodecyl sulfate polacrylamide gel electrophoresis (SDS-PAGE), and then 
transferred to Polyvinylidine difluoride (PVDF) membranes.  PVDF membranes were 
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incubated with the primary polyclonal antibodies for Melan-A (3H2639) (mouse 
monoclonal antibody raised against recombinant Melan-A), PECAM-1 (M20) (goat 
polyclonal affinity purified antibody raised against a peptide mapping at the C-terminus 
of PECAM-1 of mouse origin), CD45 (H-230) (rabbit polyclonal antibody raised against 
amino acids 1075-1304 of CD45 of human origin), macrophage marker (25F9) (mouse 
monoclonal antibody raised against mature macrophages of human origin), TGF-β (V) 
(rabbit polyclonal affinity purified antibody raised against a peptide mapping at the C-
terminus of TGF-β1 of human origin), IFN-γ (H145) (rabbit polyclonal antibody raised 
against amino acids 22-166 of IFN-γ of human origin), caspase-3 (H277), Ki67 (M19), 
and actin (I-19) (loading control) (Santa Cruz Biotechnology, Santa Cruz, CA).  Staining 
with the primary antibodies was followed by a fluorescein-linked secondary antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:600 dilution, and a tertiary antibody 
anti-fluorescein AP conjugate (NEF709, Perkin Elmer) at a 1:1000 dilution according to 
the enhanced chemifluoresescence (ECF) Western Blotting Kit (Amersham, Piscataway, 
NY).  Membranes were scanned with a FUJI FLA 2000 Fluorescence Imager and 
antibody staining intensities were measured using ImageGauge 4.1 (Fuji Photo Film Co, 
LTD).  Three tumor protein samples were analyzed from each of the three groups 
(HF20x, ndASC, HdASC) along with one non-treated control tumor protein sample.  The 
antibody staining intensities of the immunostained protein bands were normalized to the 
staining intensities of the housekeeping gene, actin, using densitometric analysis by 





Tumor tissues were fixed for one-day with 4% PFA in PBS supplemented with 
30% sucrose followed by storage in a -80oC freezer until needed for analysis.  Using an 
automated Leica cryostat, the melanoma tumor tissues were cut into 16 µm sections, and 
each tumor section was placed on a labeled gold plated microscope slide.  Tissue culture 
cells were fixed in 2% PFA/0.1% Triton-X100.  For immunohistochemical analysis all 
tissue and cell culture samples were blocked for one hour with PBS supplemented with 
2% bovine serum albumin (BSA) and 0.1 % Triton-X100 followed by over night 
incubation with the primary polyclonal antibodies, e.g., Melan-A (3H2639), PECAM-1 
(M20), and CD45 (H-230) (Santa Cruz Biotechnologies, Santa Cruz, CA) in PBS/2% 
BSA/Triton-X100.  Following three washing steps using 1x PBS, samples were incubated 
for two to six hours with the corresponding secondary antibodies consisting of F(ab')2 
fragments (host species donkey) conjugated to the fluorescent dyes Cy2TM, Cy5TM and 
DyLight549TM (Jackson ImmunoResearch, West Grove, PA) in PBS/2% BSA/Triton-
X100.  All images were acquired using a Leica DMR fluorescent microscope, or a Leica 
TCS SP2 confocal microscope.  
 
III.16. Flow Cytometry Analysis (Accuri C6) 
  Tumor samples were digested using a collagenase type 1 digest, at a final 
concentration of 254.49 units/ml (from Worthington Biochemical Corporation), for a 
total of one hour.  The digested tumors were inactivated and re-suspended within regular 
DMEM/10%FBS cell culture medium followed by filtration using 100 micrometer 
Millipore strainers to remove residual crude tissue parts.  Cell culture samples and the 
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homogenized tumor samples were centrifuged at 2000xg for 5 minutes followed by 
replacement of supernatants with staining buffer (1% BSA in HBSS buffer) and staining 
with 2 µL of primary antibody solution per 100 µL sample followed by 30 minutes 
incubation on ice.  Following staining, the samples were washed three-times including 
centrifugation at 2,000xg for 5 minutes and buffer exchange followed by final buffer 
replacement with fixation buffer (2mL of PFA in 30mL of 1x HBSS) for flow-cytometry 
analysis using an Accuri C6 Flow Cytometer.  The following antibodies were used for 
flow-cytometry: Anti-human endothelial cell marker CD31, hematopoietic/endothelial 
cell marker CD133; hematopoietic marker CD34 and HLA-DR; lymphocytic/fibroblastic 
marker CD44 and lymphocytic marker CD45; macrophage/granulocyte marker CD14, 
dendritic cell markers CD11c and CD205; stem cell markers CD73, CD90, CD105 
(eBioscience).  The matched labeled antibody isotypes were used as controls 
(eBioscience).  The Accuri C6 Flow Cytometer was calibrated and set to run for either 2 
min or collect 100,000 events with a threshold of 80,000 FSC-H and data were analyzed 
using the Accuri CFlow-Plus software.  
 
III.17. Statistical Analysis 
 The data are presented as mean ± standard error of the mean (SEM).  GraphPad 
Prism Student’s t-tests, one-way ANOVA with Tukey’s multiple comparison post-test, 
and two-way ANOVA with Bonferroni post-test were used for statistical evaluation of 




IV.1. Preliminary Results   
IV.1.1. Rationale of Preliminary Results  
 Within the majority of cutaneous melanoma cases the overproduction of 
immunosuppressive and inflammatory cytokines, such as TGF-β and interleukins (IL) 
e.g., IL-8 lowers the anti-tumor tumor immune response and contributes to the tumor 
spreading by promoting tumor cell migration and proliferation (Luca, Huang et al. 1997; 
Nurnberg, Tobias et al. 1999; Ugurel, Rappl et al. 2001).  In detail, tumor released TGF-β 
lowers the production of IL-3 and granulocyte macrophage colony-stimulating factor 
(GM-CSF) that usually play a role in the recruitment of T-lymphocytes, granulocytes and 
monocytes for phagocytic and cytotoxic degradation of abnormal cells (Enk, Becker et al. 
2006).  Consequently, the cell-based therapy with immuno-competent hematopoietic cells 
consisting of e.g., granulocytic, monocytic or neutrophilic cell populations by targeted 
tumor site injection represents a means to eliminate potential immunosuppressive tumor 
escape mechanisms.    
 The hematopoietic potential of ASC was recently demonstrated in a study 
conducted by Minana, et al. 2008, that demonstrated CD45 positive cells within the 
adherent ASC population representing a macrophage/monocyte population and were able 
to differentiation a CD45 negative and CD105 positive non-adherent ASC subset into 
hematopoietic cells that, did not express CD31 and included both CD34 negative and 
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CD34 positive cells (Minana, Carbonell-Uberos et al. 2008).  These cells were further 
able to differentiate into CD34 positive erythrocytic precursors and dendritic cell 
precursors that were CD14 positive and CD34 negative.  To develop a new cell-based 
therapy, our study aimed on generating hematopoietic differentiated HdASC from the 
total available CD45 positive and CD45 negative hematopoietic ASC population by 
creating myeloid lineages of granulocytes, monocytes, macrophages or dendritic 
progenitor cells through selective growth factor exposure to SCF-1, IL-3 and 
granulocyte-macrophage stimulating factor GM-CSF.  The potential cell types generated 
by this differentiation are thought to help in elimination of tumor cells, by their 
phagocytotic activity as well as their secretion of various activating or inhibitory 
cytokines.   
 Compared to using non-differentiated ASC that express cytokines or anti-cancer 
agents, the generated HdASC are suggested to be more beneficial when injected into a 
tumor environment due to their shorter lifespan and reduced self-renewal capacity.  For 
instance, a study conducted by Corre, Barreau et al. 2006, showed that ASC are able to 
support complete differentiation into hematopoietic progenitors and cells, but were 
unable to maintain the survival and self-renewal of normal hematopoietic stem cells 
(Corre, Barreau et al. 2006).  Thus, the generated HdASC cell-based therapy is thought as 
a combination therapy with another drug-based anti-cancer therapy to further boost the 
host immune system for tumor recognition and elimination.  Following HdASC-
dependent enhancement of tumor recognition, the residual HdASC cells are thought to be 
removed by the host's immune system with no risk of continued survival or expression of 
these differentiated cells at the tumor site.  The detailed mechanism of action regarding 
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key molecules for differentiation, immuno-suppression, and hematopoietic 
differentiation of HdASC and their effect on tumor regression remains to be determined.  
Accordingly, the preliminary study section analyzed ASC differentiation into 
hematopoietic lineages and the effectiveness of this cell-based therapy to induce 
immunologic and cytotoxic responses in vitro using methods such as 
immunocytochemistry, flow-cytometry, and ELISA analysis.  
 
IV.1.2. Analysis of ASC Hematopoietic Differentiation 
 Non-differentiated ASC (ndASC) were hematopoietic lineage differentiated into 
HdASC for 9 days in culture using hematopoietic culture medium containing growth 
factors SCF-1, IL-3 and GM-CSF according to previous culture conditions by the group 
of Minana et. al. (Minana, Carbolell-Uberos et al. 2008).  Immunocytochemistry of 
hematopoietic differentiated HdASC showed specific hematopoietic immune cell 
phenotypes including granulocytic, monocytic, dendritic cells, and macrophage similar 
appearances (Figure 4).  In addition, immunoblot staining of ndASC and HdASC showed 
increased expression of several immune cell markers, e.g., CD34 (hematopoietic marker), 
CD44 (Hyaluronic acid receptor), CD45 (leukocyte marker), and macrophage marker 
25F9 within the HdASC group compared to the ndASC group (Figure 4).  
 Further analysis of the detailed ndASC and two fractions of HdASC cell 
populations that included the attached hematopoietic progenitor colonies and the 
detached more mature hematopoietic cells was conducted using the Accuri C6 flow 
cytometer (Table 1).  The specific antibodies used for analysis included: endothelial cell 
marker CD31, hematopoietic/endothelial cell marker CD133, hematopoietic marker 
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Figure 4: Analysis of HdASC Differentiation.   
A. Phenotypes of HdASC following 9 days hematopoietic differentiation, e.g., 
granulocytes (Gr); monocytes (Mon), dendritic cells (DC), and macrophages (Mac).   
B. Immunoblotting of non-differentiated ndASC or 9 days hematopoietic differentiated 
HdASCs generated from Invitrogen (Inv) purchased ASC.  Staining for CD45 (general 
leukocytic marker), CD44 (surface adhesion marker), macrophage marker 25F9 
(MacM), and CD34 (hematopoietic marker).  Table summarizes fold up-regulation of 
expression of HdASC compared to the ndASCs control (1 fold) normalized to the 




Table 1: Analysis of Hematopoietic Cell Differentiation 
 Table lists the percentage of cell surface marker expression in ndASC, attached 
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 CD34 and HLA-DR, lymphocytic/fibroblastic marker CD44 and lymphocytic marker 
CD45, macrophage/granulocyte marker CD14, dendritic cell markers CD11c and CD205, 
stem cell markers CD73, CD90, and CD105 (Table 1).  The corresponding antibodies 
were directly coupled to fluorophores APC, PE, PE-Cy7, PE-Cy5.5, and FITC for 
differential staining.   
 In order to determine the percent of antibody staining in correlation to the total 
cell population the experimental samples were gated versus the antibody isotype controls.  
The ndASC group showed the typical antibody staining for non-differentiated 
mesenchymal stem cells including CD73 (74.1%), CD90 (65.5%), CD105 (64%) and 
CD44 (61.1%) with low levels of hematopoietic cell markers CD 45 (16%), CD34 (20%), 
CD205 (19.2%), CD11c (5.3%) and low expression of endothelial cell markers CD133 
(14.8%) and CD31 (6.0%).  Compared to ndASC, the attached fraction of HdASC 
hematopoietic progenitor cells showed no detectable levels of CD44 expression and 
showed a similar CD105 expression (66.0%)and a lower percentage of staining for the 
mesenchymal stem cell markers CD73 (51.4%), CD90 (58.2%).  In addition this HdASC 
fraction demonstrated similar levels of hematopoietic cell markers CD34 (15.6%), CD45 
(20.4%), CD205 (13.6%), CD14 (10.9%) and an increase in percent cells positive for 
dendritic cell marker CD11c (14.1%) similar to the observed dendritic cell differentiation 
reported by Minana et. al. (Minana, Carbolell-Uberos et al. 2008).  Also, coherent with 
previous observations by Minana et al., expression for the hematopoietic/endothelial cell 
marker CD31 and the HLA-DR marker was higher in the HdASC progenitor group with 
15.6% and 13.3%, respectively, compared to the ndASC group (Minana, Carbolell-
Uberos et al. 2008).  As expected, the more mature hematopoietic HdASC floating in 
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suspension showed a down-regulation in the corresponding stem cell markers CD73 
(39.5%), CD90 (42.6%), and CD105 (39.2%) indicating successful differentiation into a 
more mature cellular phenotype.  In addition, the HdASC suspension cells demonstrated 
similar levels in hematopoietic markers compared to the ndASC group for the following 
antibodies: CD11c (4.9%), CD45 (13%), CD31 (5.3%), CD205 (21.6%), HLA-DR 
(4.5%).  Further, this cell group also demonstrated an up-regulation in expression of the 
hematopoietic/endothelial cell marker CD133 with 28.6% and an up-regulation in the 
hematopoietic/ marker CD34 (23.7%) similar to the Minana et al. observed increase in 
CD34 expression within the detached HdASC cell population (Minana, Carbolell-Uberos 
et al. 2008).  Correspondingly, the observed lower percentages in detected hematopoietic 
cell markers within the suspension HdASC group compared to the attached progenitor 
cell group might also be explained with the complexity of more mature differentiated 
cells created that might have lost certain cell surface markers and also, the vast variety of 
the created cells within the total population.  
 
IV.1.3. Cellular Effects of ndASC and HdASC on B16-F1 Cell Co-Culture   
 To determine the cellular effect of B16-F1 cells in co-culture with cell-based 
therapies, human fibroblasts (HF), ndASC, and HdASC were plated at a concentration of 
1x105 cells/well followed by addition of 1x105 cells/well B16-F1 cells after one hour.  
Co-cultures were analyzed after one-day using phase-contrast microscopy (Figure 5).  
One-day co-cultures of HF1 and ndASC demonstrated similar B16-F1 cell growth 




Figure 5: Analysis of One Day Co-Culture of B16-F1 Cells with ndASCs and HdASCs. 
A. Phase-contrast microscopy of B16-F1 cell co-cultures with 1.ndASC and 2.HdASC. 
B. Immunocytochemistry of B16-F1 cell co-cultures with 1.ndASC and 2.HdASC. 
CFDA-SE stained ASC are in green, and macrophage marker (MacM) staining is in 
blue.  
C. Murine HdASC stained for CD45 leucocytic marker in red co-cultured with CFDA-SE 
stained B16-F1 cells in green.  B16-F1 cells form clusters with human HdASC 
positive for MacM and murine HdASC positive for CD45 (open arrows) that appear to 
be phagocytic towards melanoma cells. 
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 with hematopoietic differentiated HdASC demonstrated detachment of a majority of 
HdASC cells into cell clusters.    
 To determine the role of HdASC on cell cluster formation, human 
fibroblasts HF1, ndASC, and HdASC were stained with the green fluorescent vital dye 
Vybrant® CFDA-SE Cell Tracer (Invitrogen) and plated as described above followed by 
fixation of cells after one day of culture and immunocytochemistry staining using a 
primary antibody for macrophage marker 25F9.  Analysis of immunocytochemistry by 
confocal microscopy demonstrated appearance of hematopoietic differentiated cells on 
top of the melanoma cell layer (Figure 5).  In addition, some of the melanoma cells 
appeared to be phagocytosed by an immune cell cluster that stained positive for HdASC 
and macrophage marker.  To exclude that the observed immune cell cluster formation 
was due to the interspecies immune reaction of human HdASC versus mouse B16-F1 
cells, murine adipose tissue-derived stem cells (mASC) were generated from C57BL/6 
mice that match the genetic background of the B16-F1 mouse cell line.  Accordingly, the 
generated mASC were differentiated into hematopoietic lineages using similar cell 
culture conditions of 9 day differentiation as described for human stem cells above.  For 
better immunocytochemistry results, non-labeled murine HdASC were co-cultivated with 
the CFDA-SE labeled B16-F1 mouse melanoma cells according to similar culture 
conditions as described above.  One-day B16-F1/hdASC co-cultures were fixed and 
stained by immunocytochemistry using a primary antibody for CD45 (Figure 5).  
Immunocytochemical analysis demonstrated a similar appearance of HdASC immune 
cell clusters that stained positive for CD45 and seemed to have phagocytic activity 
towards the melanoma cell layer suggesting that the ASC-dependent effect is not 
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correlated to potential interspecies immune reactivity but to a more general ASC-
dependent immune response. 
 
IV.1.4. Cytokine Effects of HF1, ndASC and HdASC Cell Culture Supernatants on 
B16-F1 Cells   
 To determine if alterations in cytokine secretion within the HdASC group play a 
role in the observed cell cluster formation, B16-F1 cells were grown for one-day in 0.2 
micron sterile filtrated culture media taken from three day HF, ndASC, and HdASC 
cultures and fresh DMEM to remove any cellular components and analyzed by phase 
contrast microscopy (Figure 6).  Similar cell cluster formations were observed in the 
group that received the HdASC extracted culture medium.  In contrast, cells 
demonstrated good attachment and viability in the other groups similar to the DMEM 
control.   
 To further determine if the HdASC derived medium has an effect on cell viability 
and proliferation, the cells were analyzed for their ability to metabolize the 
proliferation/cell viability dye Alamar Blue into a fluorescent component that can be 
measured at 620nm emission (Figure 6).  The HdASC extracted cell culture medium 
demonstrated a significant (p<0.001) decrease in B16-F1 melanoma Alamar Blue dye 
conversion with a fluorescence intensity of 1,278±28.28 compared to the DMEM 
medium control with 1,542±13.89.  All other groups observed similar fluorescent 





Figure 6: Effect of HF1, ndASC, and HdASC Cell Culture Supernatants on B16-F1 
Cell Growth. 
A. Phase contrast analysis of B16-F1 cells grown for one-day in DMEM and filtered 
cell culture supernatants obtained from three-day HF1, ndASC, and HdASC culture.  
Cell cluster formation and lower cell viability of B16-F1 cells grown in HdASC-
derived culture supernatant were observed.   
B. Alamar blue proliferation assay of B16-F1 grown for one-day in DMEM and 
filtered cell culture supernatants obtained from three-day HF1, ndASC, and HdASC 
culture.  Significant differences in proliferation activity (p-value<0.001) were seen 
between the HdASC and DMEM cell culture supernatant. 
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IV.1.5. Summary of Preliminary Data 
 In summary, our preliminary data suggests successful differentiation of ASC into 
a hematopoietic lineage with macrophage/leukocyte characteristics.  This includes the 
capability of cytotoxic responses and functional cytokine secretion that is suitable for the 
purpose of a cell-based immunotherapy for the induction of melanoma tumor regression.  
 
IV.2. Results of the Main Study  
IV.2.1. Animal Study  
 The study included a total of (n=31) C57BL/6 mice that were initially 
subcutaneously injected into the right thighs with 200 µL of 5x106 cells/mL mouse 
melanoma B16-F1 cells in order to establish tumor xenografts (Figure 7).  Animals were 
divided into two control groups of a) one (n=1) animal with no further treatment and b) 
ten (n=10) animals that received 200 µL of 5x106 cells/mL CFDA-SE labeled human 
fibroblasts (HF20x).  In addition, two experimental groups were established including c) 
ten (n=10) animals that received 200 µL of 5X106 cells/mL CFDA-SE labeled human 
non-differentiated human ASC (ndASC) and d) 200 µL of 5x106 cells/mL CFDA-SE 
labeled hematopoietic differentiated human ASC (HdASC).  Four days after initial B16- 
F1 xenograft injection, cellular therapies for groups b), c) and d) were applied by one-
time direct injection of the corresponding cells, e.g., HF20x, ndASC or HdASC into the 
mid portion of the tumor site with average tumor diameter of 3 mm at the time of 
injection.  Mouse body weights were recorded daily, and tumor growth rates were 
photographed and measured every second day by a digital caliper for determination of 
tumor area extension.  Four days after HF20x, ndASC and HdASC implantation the 
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Figure 7: Timeline of the Animal Experiment. 
 This figure shows the timeline for the experiment from the start (thawing of the B16-
F1, HF20x, and ASC) to end (tumor excision).  The figure also includes days when the mice 
were ordered, received in the LAR facility, days mice were weighed and tumors measured, 
when cells were stained with CFDA-SE, when cell differentiation started, and what days cells 
were injected into the mice and the tumors. 
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 animals were sacrificed by CO2 inhalation.  Blood from their inferior vena cava was 
collected, and photographs were taken of each tumor followed by tumor excision, and 
weight determination.  Groups b) HF20x (n=10), c) ndASC (n=10) and d) HdASC (n=10) 
were subdivided into two subgroups of 1) (n=6) animals for immunohistochemical 
analysis and 2) (n=4) animals for immunoblotting and ELISA analysis that included 
further partitioning of (n=2) tumors from each group for flow cytometry analysis. 
 
IV.2.2. Mouse Body Weight Determination as a Parameter for Non-Metastatic 
Tumor Growth  
 To assure local subcutaneous positioning of the implanted B16-F1 tumor 
xenograft and eliminate signs of metastatic spreading to vital organs, body weights of the 
mice were determined daily.  Average mouse body weights demonstrated a slight 
increase in all treatment groups throughout the entire experiment with no significant 
increases or decreases in the weights between groups or individuals in each treatment 
group (Figure 8).  Initial mouse body weight averages on the day of B16-F1 mouse 
melanoma cell injection were 25.85±0.32 g for the HF20x group, 25.96±0.39 g for the 
ndASC group, and 25.93±0.32 g for the HdASC group.  The final average body weights 
for the mice were 26.19±0.39 g for the HF20x group, 26.35±0.43 g for the ndASC group, 
and 26.31±0.36 g for the HdASC group.  Analyzing the body weights for the mice over 
the entire time frame of the experiment using two-way ANOVA analysis showed no 
significant difference in average body weight increases between the treatment groups, but 




Figure 8:  Determination of Mouse Average Body Weights (g). 
 Graph summarizes the average body weights (g) of mice over the eight day time 
period of the experiment.  Two-way ANOVA was done starting at Day 0 of cell-based therapy 
injections, and showed no significant treatment related changes in average body weights, but 
showed significant (p-value<0.0001) average weight gain over time for all treatment groups.   
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IV.2.3. Specific Aim 1: To test the hypothesis that ASC promote melanoma 
regression through differentiation into immuno-competent hematopoietic cell 
lineages.  
 
IV.2.3.1. Rationale for Specific Aim 1  
 Recent in vitro and animal-based studies have demonstrated the potential of 
mesenchymal stem cells such as BSC and ASC to target and promote tumor regression of 
different tumor types including glioblastoma, Kaposi’s sarcoma, ovarian cancer, and lung 
melanoma metastases (Maestroni, Hertens et al. 1999; Nakamura, Ito et al. 2004; 
Studeny, Marini et al. 2004; Khakoo, Pati et al. 2006).  The hematopoietic potential of 
ASC was recently demonstrated in a study conducted by Minana, et al. (Minana, 
Carbonell-Uberos et al. 2008).  Correspondingly, our study aimed on generating 
hematopoietic differentiated HdASC from the total available CD45 positive and CD45 
negative hematopoietic ASC population by creating myeloid lineages of granulocytes, 
monocytes, macrophages or dendritic progenitor cells through selective growth factor 
exposure to SCF-1, IL-3 and granulocyte-macrophage stimulating factor GM-CSF.  
According to our preliminary data, we were able to successfully generate HdASC of 
granulocytic, monocytic, macrophage and dendritic cell types that demonstrated both, 
cellular and cytokine effects against melanoma cells supporting the potential of HdASC 
to eliminate tumor cells by their phagocytotic activity as well as their secretion of various 
activating or inhibitory cytokines a cytotoxic anti-tumor response (Corre, Barreau et al. 
2006; Kilroy, Foster et al. 2007).  In detail, a HdASC-dependent cytotoxic tumor 
response might include ASC-dependent secretion of immunogenic cytokines such as IL-
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6, SCF, and GM-CSF that promote recruitment of other circulating immune cells such as 
monocytes and granulocytes that are suggested to contribute to tumor regression 
(Majumdar, Thiede et al. 2000; Ohlsson, Varas et al. 2003; Wang, Liu et al. 2003).  
Besides the corresponding increase in phagocytotic activity, the ASC-promoted release of 
cytotoxic cytokines such as IL-2 and TNFα from cytotoxic T-cells and macrophages 
might act on reduction of melanoma cell proliferation, and increase tumor cell apoptosis 
(Ostanin, Chernykh et al. 1997; Boyman, Surh et al. 2006).  Thus, the factors mediating 
the antitumor activity are relatively unclear and remain to be determined.  The specific 
aim 1 determines the melanoma tissue-specific cellular effect of ndASC and HdASC in 
vivo using a mouse melanoma xenograft model. 
 
IV.2.4. Effect of HF20x, ndASC and HdASC on Melanoma Growth   
 To test if ASC can promote melanoma regression, changes in tumor area 
extension and weight of HF20x, ndASC, and HdASC-treated tumors were compared.  
Against our expectations, the HdASC group demonstrated a non-significant increasing 
trend (One-way ANOVA, p=0.1516; t-test, p=0.3) in average tumor weights with 
0.0811±0.024 g compared to the ndASC (0.0525±0.024 g) and the HF20x (0.0497±0.016 
g) (Figure 9).  Since tumor weight measurements do not reflect any individual changes in 
tumor growth over time, additional tumor extension measurements were done from day 0 
(cell-based therapy injections) to day 4 (tumor harvest).  Due to limitations of three-
dimensional measurements regarding smaller size tumors, tumor area extension was 
determined by calculating the product of digital caliper-measured tumor length and the 
width (Figure 9).   
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Figure 9: Tumor Growth Determination of Cell-based Therapy Treatment Groups by 
Average Weight (g) and Average Tumor Area Extension (mm2) Measurements. 
A. Graph represents the average tumor weight for each individual treatment group at day of 
B16-F1 melanoma tumor excision.  The HdASC group demonstrated a non-significant 
increasing trend (One-way ANOVA p-value=0.1516; t-test p-value=0.3) in average tumor 
weight.  
B. Graph represents average tumor area extension (mm2) measured from Day 0 to Day 4 
using a digital caliper.  Significant differences were seen between HF20x and HdASC 
groups on Day 2 (p-value<0.01), and on Day 4 (p-value<0.05). 
C. Graph represents the Digital Caliper measured tumor area (mm2).  Significant differences 
were seen between HF20x and HdASC groups on Day 2 (p-value<0.05).  
D. Representative images of melanoma tumors for each treatment group.   
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 Confirming the previously observed increasing trend in tumor weights in presence 
of HdASC treatment, the HdASC group demonstrated a treatment-dependent significant 
increase (Two-way ANOVA, p<0.01) in average tumor area extension from 61.04±6.908 
mm2 at day 0 to 78.47±5.13 mm2 at day 4 of treatment compared to the HF20x control 
(58.8±8.492 mm2 on day 0 to 53.52±4.035 mm2 on day 4), and the ndASC group 
(54.06±5.95 mm2 on day 0 to 68.45±10.05 mm2 on day 4).  The HF20x and ndASC 
groups demonstrated no significant changes in tumor area extension both, in two-way 
ANOVA and t-tests.  In addition, the HF20x control group demonstrated a decreasing 
trend in average tumor area extension at day 2 of treatment with 45.33±6.255 mm2.  The 
observed day 2 decrease in HF20x tumor area extension was further confirmed when 
calculating the increase in percent average tumor area extension in correlation to the day 
0 average tumor area values with a proportional 10.41±14.65 percent decrease in tumor 
area of the HF20x group versus a 38.38±16.39 treatment-dependent increase within the 
HdASC group (Two-way ANOVA, p<0.05) at day 2 (Figure 9).  In comparison to the 
initial drop in tumor area extension, the HF20x group demonstrated a 6.29±12.74 percent 
tumor area increase at day 4 of treatment compared to 31±18.01 percent area increase in 
the ndASC group, and a maintained 39.11±13.22 percent area increase in the HdASC 
group. 
 
IV.2.5. Identification of Distinct Cell Clusters Within Tumors Through Comparison 
of Control Cell Populations 
 To determine distinct cell clusters within the tumors of different cell-based 
therapy groups, different control cell populations including B16-F1 melanoma cells, 
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ndASC, HF20x, mouse spleen, and mouse blood samples were analyzed by the Accuri 
C6 flow cytometer.  Four distinct cell population clusters, marked as gates P1, P2, P4 and 
P5 were identified using the forward scatter (FSC) and side scatter (SSC) option of the 
flow cytometer software (Figure 10).  For instance, the B16-F1, ASC, and HF20x cell 
populations had a majority of the cells in the P1 and P5 gates (P1: 28.7%, B16-F1; 
24.2%, ASC; 24.4%, HF20x versus P5: 30.3%, B16-F1; 15.4%, ASC 27.5%, HF20x) 
with the P1 gate representing the cells of the highest molecular weight and granularity 
and, the P5 gate representing cells with the smallest molecular weight and granularity 
including some cellular debris.  To distinguish hematopoietic cell populations within the 
different treatment groups, a mouse spleen derived from a healthy non-tumor carrying 
control mouse was analyzed by the flow-cytometry.  Analysis of mouse spleen 
demonstrated a very abundant cell population cluster within the P4 gate (67.5% of total 
counts) that might indicate cells of lymphocytic origin.  In addition, a mouse blood 
sample was derived from a healthy non-tumor carrying control mouse and analyzed for 
detection of regular blood cell populations.  The mouse blood demonstrated only 6% of 
total counts in the P4 gate together with a unique cell cluster marked with the P2 gate of 
15.9% that might be of lymphocytic origin, and also contained abundant counts in the P5 
gate with 34.7% that might represent non-clotted red blood cells and cellular debris.  
Regarding the B16-F1, ASC and HF20x cells, only small percentages of counts were 
observed in the two lymphocytic population gates, e.g., P2 and P4 supporting 
establishment of distinct gates for identification of changes in hematopoietic cells within 




Figure 10: Determination of Distinct Cell Clusters from Collected Control Cell 
Populations Measured by Flow Cytometry. 
 Flow cytometry of different cell populations e.g. A) B16-F1 cells, B) Adipose Stem 
Cells (ASC), C) HF20x, D) mouse spleen, and E) mouse blood analyzed by forward scatter 
(FSC) and side scatter (SSC) for determination of cell size and complexity.  F) Cell cluster 
gates established for all analyzed cell population samples.  Total cell populations for B16-F1, 
ASC, and HF20x cells are shown in the left panel and the middle panel shows the 
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 The previously identified cell cluster gates, e.g., P1, P2, P4, and P5 were applied 
to identify distinct cell populations within enzymatic digested tumors selected from each 
treatment group tumors, e.g., HF20x, ndASC, HdASC, and non-treated control (Figure 
11).  
 Flow cytometry analysis showed distinct cell cluster counts in all four gates, e.g., 
P1, P2, P4, and P5 within all tumor groups.  Compared to the non-treated tumor that 
demonstrated 18.9% of total cell counts in the P1 gate, the different cell-based treatment 
groups demonstrated higher percentages of total counts, e.g., 33.6% HF20x, 24.9% 
ndASC, and 22.6% HdASC which is coherent with the larger cell sizes of these injected 
cells.  In addition, compared to the 6.9% cell counts in the P4 gate of the non-tretated 
control the HF20x group and the HdASC group demonstrated higher appearance of 
counts in this lymphocytic cell population gate with 11.1% HF20x, and 8.2% HdASC 
that might indicate potential influx of inflammatory cells into the tumor or could account 
for eventual injected hematopoietic-differentiated stem cells with regards to the HdASC 
group.  In comparison to the HF20x and HdASC counts, the counts for the P4 cluster of 
the ndASC group were similar to counts of the non-treated tumor sample (5.3%).   
 
IV.2.6. Detection of Treatment-Residual CFDA-SE Labeled Cells Within the Tumor 
Environment  
 Further flow cytometry analysis was done on collagenase digested tumors in order 
to determine treatment-residual CFDA-SE labeled HF20x, ndASC, or HdASC cells 
within the melanoma tumor environment (Figure 12).  The non-treated tumor was used as 
an isotype control for comparison to all other treatment tumor groups, e.g., HF20x, 
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Figure 11: Determination of Distinct Cell Clusters from Collected Melanoma Tumors 
Measured by Flow Cytometry. 
 Flow cytometry of different melanoma treatment groups, e.g. C) HF20x, D) ndASC, 
E) HdASC, and B) non-treated control tumor analyzed by forward scatter (FSC) and side 
scatter (SSC) for determination of cell clusters with distinct cell size and complexity.  A) Cell 




Figure 12: Flow Cytometry Detection of CFDA-SE Stained Therapeutic Cells in B16-F1 
Tumor Samples. 
 A) to C) Determination of CFDA-SE stained therapeutic cells within A) HF20x, B) 
ndASC, and C) HdASC treated tumor samples using flow cytometry.  Histograms with the non-
treated trumor containing no CFDA-SE stained cells as a negative control (left panel), overlay of 
HF20x, ndASC, and HdASC tumor samples with non-treated control (middle panel), magnification 
of middle panel-derived region of interest (right panel).  D) Left Panel: Flow cytometry histograms 
of un-stained ASC cell sample as a negative control for CFDA-SE stained ASC.  Right Panel: 
Overlay of CFDA-SE stained ASC with un-stained ASC.  E) Graph summarized average 
percentage of CFDA-SE stained cells detected in flow cytometry analysis of panels A, B, and C. 
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 ndASC, and HdASC in order to help determine eventual green fluorescence in the 
according channel.  By overlaying the histograms of non-treated versus cell-therapy 
treated tumors, an approximate determination of CFDA-SE labeled cell counts and 
percentage in each of the treatment tumors was measured.  The histogram overlays were 
able to show that only a small percentage of the total cell counts in each group were 
positive for CFDA-SE fluorescence, e.g., 0.2% of total cell counts were positive in the 
HdASC group, 2.5% were positive in the ndASC sample group, and 0.7% were positive 
in the HF20x group. 
 To confirm the flow-cytometry observations, cryostatic sections of cell-therapy 
treated tumors were analyzed by immunohistochemistry using fluorescence and confocal 
microscopy (Figure 13).  To distinguish between the tumor cells and the CFDA-SE 
labeled cells from cell-based therapies, some histology sections were stained with 
melanoma-specific primary antibody Melan-A followed by staining with secondary 
antibody coupled to the fluorophore cy3 (Figure 13).  Existence of the treatment residual 
CFDA-SE stained cells was confirmed for all treatment groups with distribution of cells 
inside and along side the edges of the tumors.  In addition, cell morphologies 
demonstrated clear differences between the CFDA-SE stained cells of each of the 
treatment group with no visible signs of cell death or necrosis.  For instance, CFDA-SE 
stained HF20x cells showed their typical fibroblastic appearance with long stretched cell 
shapes that formed distinct tissue patches within the tumor (Figure 13).  In coherence 
with the mixed tissue type of adipose tissue-derived mesenchymal stem cells, CFDA-SE 
stained cells of the ndASC treatment group were more loosely organized and showed 
different cellular shapes of e.g., fibroblastic, neuronal, and endothelial cell, etc. 
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Figure 13: Histology of CFDA-SE Stained Therapeutic Cells in B16-F1 Tumor Samples.   
 Left panel displays fluorescence microscope images taken at 5x objective representing 
CFDA-SE labeled HF20x, ndASC, and HdASC therapeutic cell populations inside melanoma 
tumors.  CFDA-SE labeled cells in the melanoma tumors are bright green and marked by open 
arrows.  Middle panel displays confocal microscope images of CFDA-SE stained treatment 
cells in green.  Right panel displays the overlay of CFDA-SE stained treatment cells and 
melanoma-specific Melan-A stained cells in red.  Size bar is representative of magnification 




 appearance suggesting a more mature functional tissue cluster (Figure 13).  The CFDA-
SE stained cells of the HdASC treatment group demonstrated rounded cellular shapes, 
and were distributed more loosely within longitudinal cell clusters that also demonstrated 
migration into the adherent tumor tissue (Figure 13).   
 Besides the above mentioned lack of visible signs of cell death, Western blotting 
analysis for caspase-3 expression further confirmed lack of apoptotic activity by yielding 
no changes in caspase-3 levels and lacked appearance of active cleaved caspase 3 
throughout all the treatment groups (data not shown).  Also, Western blotting analysis 
demonstrated no changes in overall expression of the proliferation marker Ki67 
throughout the different treatment groups (data not shown). 
 
IV.2.7. Determination of Treatment-Dependent Increase in Tumor-Specific Cells  
 In order to determine if the observed treatment-dependent increase in tumor 
weight and area extension in the HdASC group were due to an increase in proliferation of 
tumorigenic cells, expression of the melanoma specific marker Melan-A was analyzed by 
Western blotting (Figure 14).  Against our expectations, a significant decrease (p<0.01, 
one-way ANOVA) in Melan-A expression was observed in the ndASC group 
(0.89±0.017, t-test: p<0.01), and the HdASC group (0.75±0.019), that showed the lowest 
expression of Melan-A in comparison to the HF20x control group (1±0.042, t-test: 
p<0.01) suggesting reduced tumor cell proliferation in the HdASC group.  Western blot 
analysis showed three major bands above the normal band marker for Melan-A (17-22 
kDa).  Since Melan-A represents a membrane integrated protein, our protein purification 


































































Figure 14: Melan-A Expression Within B16-F1 Mouse Tumor.  
A. Western blot membrane showing distinct bands of Melan-A expression in 
Non-treated (n=1), HF20x (n=3), ndASC (n=3), and HdASC (n=3) tumors. 
B. Graph represents densitometric analysis of Melan-A staining in A) expressed 
as fold Melan-A expression.  Samples were normalized to the actin loading 




explain Western-detection of higher molecular weight bands and has also been observed 
by other groups (Chen, Stockert et al. 1996).   
 
IV.2.8. Determination of Treatment-Dependent Tumor Blood Vessel Formation  
 In order to determine if the observed treatment-dependent increase in tumor 
weight and area extension in the HdASC group were due to an increased blood vessel 
formation, tumor sample expression of the endothelial cell marker platelet/endothelial 
cell adhesion molecule-1 (PECAM-1, also CD31) were tested by Western blotting 
(Figure 15).  The chosen PECAM-1 (CD31) antibody was a goat polyclonal antibody 
with cross-reactivity towards PECAM-1 of mouse, rat, and human origin.  In correlation 
with the increased tumor sizes in the HdASC group, we observed a non-significant 
increasing trend (t-test, p= 0.09) in expression levels of PECAM-1 in the HdASC group 
(1.885±0.48) compared to the ndASC group (1.109±0.086), and the HF20x control group 
(0.828±0.1).  Both one-way ANOVA and t-tests were used in order to determine 
significance between the treatment groups, and no significance was observed between the 
three treatment groups. 
 To further determine differences in tumor blood vessel formation, three cryostatic 
sections from the beginning, middle, and end of each tumor sample with a total of n=6 
samples in each treatment group were selected for analysis.  Blood vessels were counted 
in a blinded fashion for determination of average blood vessel numbers/tumor in each 
treatment group (Figure 15).  The HdASC group and the ndASC group demonstrated 
significant increases in average number of blood vessels per tumor with 4.7±1.12 and 








































































































Figure 15: Determination of the Blood Vessel Formation Following Cell-based Therapies.   
A. Representative confocal microscope images that demonstrate the blood vessel-specific 
PECAM-1 staining in red of the HF20x, ndASC, and HdASC treated tumors.  Size bar is 
representative of magnification used in all slides.  White arrows show representative blood 
vessels counted for analysis. 
B. Western blot membrane showing distinct bands of PECAM-1 expression in Non-treated 
(n=1), HF20x (n=3), ndASC (n=3), and HdASC (n=3) tumors. 
C. Graph represents densitometric analysis of PECAM-1 staining in A) expressed as fold 
PECAM-1 expression.  Samples were normalized to the actin loading control and then 
compared to the HF20x control that was set to 1-fold.   
D. Graph represents the average number of blood vessels in the melanoma tumors for HF20x 
(n=6), ndASC (n=6), and HdASC (n=6) treatment groups.  Vessel counts were done from 
selected microscope slides from the beginning, middle, and end of representative 
cyrostatic sections from each tumor.  Significant changes were seen between the HF20x 
and ndASC group, and the HF20x and HdASC group (p-value<0.05).      
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ANOVA analysis showed significant differences between the treatment groups 
(p=0.0054), and t-test analysis showed significance between the HdASC group and the 
HF20x group (p=0.0069), as well as between the ndASC group and the HF20x group 
(p=0.0016).  
 
IV.2.9. Identification of the Treatment-Dependent Immunogenic Tumor Response  
 To determine the general appearance of CD45 positive cells including cells of 
mouse and ASC-derived origin, slides of tumor sections were analyzed by confocal 
microscopy using immunohistochemical staining with a CD45-specific antibody that 
cross-reacted with CD45 of mouse and human origin (Figure 16).  The immuno-histology 
for CD45 in HF20x tumor sections demonstrated only limited appearance of CD45 
stained cells in comparison to higher appearance of CD45 stained cells in the ndASC and 
the HdASC groups.  Interestingly, the ndASC stained tumor sections showed some 
CFDA-SE stained ASC cells that also stained positive for CD45, indicating spontaneous 
differentiation of ndASC into hematopoietic/lymphocytic cells (Figure 16).  In addition, 
the HdASC tumor sections contained CFDA-SE stained ASC that appeared to form blood 
vessels (Figure 16).  
 To further identify potential macrophage differentiation originating from human 
ASC, Western blotting analysis included the macrophage marker 25F9-specific primary 
antibody, a mouse monoclonal antibody raised against macrophages of human origin 
(Figure 17).  Western blotting detection of this specific macrophage surface marker 25F9 
was chosen according to previous publications that demonstrated increased appearance of 
macrophages expressing this specific surface receptor in more aggressive melanoma  
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Figure 16: Determination of Leukocyte Immune Response with CD45 Antibody 
Following Cell-based Therapy.   
 Left panel displays confocal microscope images of CFDA-SE stained treatment cells 
in green.  Right panel displays the overlay of CFDA-SE stained treatment cells and melanoma-
specific CD45 stained cells in red.  Size bar is representative of magnification used in all 
slides.  Open arrows indicate existence of CD45 positive cells within the CFDA-SE stained 
ndASC and HdASC therapeutic cell population.  The filled arrow represents a cell group of 
CFDA-SE stained HdASC in the beginning stage of blood vessel formation.  Also, streaks of 
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Figure 17: Analysis of Macrophage Immune Response Following Cell-based Therapy.  
A. Western blot membrane showing distinct bands of Macrophage Marker expression in 
Non-treated (n=1), HF20x (n=3), ndASC (n=3), and HdASC (n=3) tumors. 
B. Graph represents densitometric analysis of Macrophage Marker staining in A) 
expressed as fold Macrophage Marker expression.  Samples were normalized to the 
actin loading control and then compared to the HF20x control that was set to 1-fold.  
The HdASC group demonstrated a significant (t-test p-value<0.05) increase in 
expression levels of the macrophage marker 25F9 with 1.454±0.14 fold expression 
compared to no changes in the ndASC group (0.993±0.14), and the HF20x group 
(1±0.05). One-way ANOVA was tending towards significant differences between the 




tumors (Brocker, Zwadlo et al. 1987).  According to the previous data, the HdASC group 
demonstrated a significant (t-test p<0.05) increase in expression levels of the macrophage 
marker 25F9 with 1.454±0.14 fold expression compared to no changes in the ndASC 
group (0.993±0.14), and the HF20x group (1±0.05).  One-way ANOVA was tending 
towards significant differences between the HF20x and the HdASC group (p=0.057). 
 
IV.2.10. Specific Aim 2: To test the hypothesis that ASC promote melanoma 
regression through alteration of melanoma-related cytokine and mitogenic 
responses.   
 
IV.2.10.1. Rationale for Specific Aim 2  
 The phagocytotic activity of macrophages, neutrophils, granulocytes, and natural 
killer cells (NK) that is supported by CD4+ and CD8+ T-lymphocytes, play a key role in 
anti-tumorigenic responses (Nawrath, Pavlovic et al. 2001; Xu, Gu et al. 2004).  The 
melanoma-associated release of the immunosuppressive cytokine TGF-β reduces the IL-3 
and GM-CSF-dependent recruitment of T-lymphocytes, granulocytes, and monocytes 
from the bone marrow (Enk, Becker et al. 2006).  The introduction of ASC at the tumor 
site is thought to increase the immunologic anti-tumor response by enhancing cytokine 
secretion for generation of ASC-derived immune cells and recruitment of circulating 
immune cells for promotion of tumor regression (Ohlsson, Varas et al. 2003).  The ASC 
secretion of immunogenic cytokines such as IL-6, stem cell factor (SCF-1), and GM-CSF 
together with the release of other cytokines from recruited circulating immune cells such 
as IL-7, granulocyte-colony stimulating factor G-CSF, GM-CSF and pro-inflammatory 
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cytokines (IL-6, IL-8, IL-12, and TNFα) might also contribute to tumor regression 
(Majumdar, Thiede et al. 2000; Wang, Liu et al. 2003; Corre, Barreau et al. 2006; Kilroy, 
Foster et al. 2007).  In addition, anti-proliferative, pro-apoptotic, and anti-angiogenic 
cytokines released from ASC and invading immune cells, e.g., IL-2, TNFα, IFN-γ, and 
TGF-β play a role in the promotion of tumor growth or regression (Ostanin, Chernykh et 
al. 1997; Boyman, Surh et al. 2006; Elzaouk, Moelling et al. 2006).  The specific aim 2 
determines the cytokine and growth factor melanoma tissue-specific effect of ndASC and 
HdASC in vivo using a mouse melanoma xenograft model. 
 
IV.2.11. Determination of Alterations in Tumor Tissue Cytokine Response 
 To determine treatment-dependent changes in cytokine response, we focused on 
changes in cytokine secretion of TGF-β, a protein that controls proliferation, cellular 
differentiation, and has been found to show alterations in expression during 
tumorigenesis.  For instance, TGF-β has been demonstrated to act as a tumor suppressor 
in early tumorigenesis, and then later can act as an enhancer for tumor progression 
(Bierie and Moses 2006).  Western blot analysis of homogenized tumor samples 
demonstrated no significant changes in TGF-β expression levels regarding the HF20x 
group (1±0.12), ndASC group (1.147±0.06), and the HdASC group (0.9910±0.10) 
(Figure 18).  Both one-way ANOVA and T-tests were used in order to determine 
significance between the treatment groups, yet no significance was observed between the 
three treatment groups.  Western blot analysis showed a band above the normal TGF-β 
marker band (12.9/39 kDa), that might represent dimeric forms of TGF-β or residual 
remnants of the active multimeric TGF-β protein complex that is formed through  
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Figure 18: Determination of TGF-β Cytokine Response Following Cell-based Therapy.     
A. Western blot membrane showing distinct bands of TGF-β expression in Non-treated 
(n=1), HF20x (n=3), ndASC (n=3), and HdASC (n=3) tumors. 
B. Graph represents densitometric analysis of TGF-β staining in A) expressed as fold 
TGF-β expression.  Samples were normalized to the actin loading control and then 
compared to the HF20x control that was set to 1-fold.   
C. Graph represents the expression levels of TGF-β (pg/ml) in melanoma tumors of the 
different treatment groups (Non-treated (n=1), HF20x (n=3), ndASC (n=3), and 
HdASC (n=3)) analyzed in triplicates.  One-way ANOVA and t-test analysis did not 
show any significant differences between any of the treatment groups.   
D. Graph represents the expression levels of TGF-β (pg/ml) within the mouse plasma of 
the different treatment groups (Non-treated (n=1), HF20x (n=3), ndASC (n=3), and 
HdASC (n=3)) analyzed in triplicates.  One-way ANOVA and t-test analysis did not 
show any significant differences between any of the treatment groups.      
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disulfide-bonds.  In addition, TGF-β expression levels were tested in ELISA analysis as a 
more sensitive assay in TGF-β detection (Figure 18).  Similar to the Western-blotting 
data, no significant changes could be detected in homogenized tumors and in the blood 
plasma levels.  Overall, the HF20x group (1,543±530.4 pg/mL) demonstrated the highest 
TGF-β expression levels present in the homogenized tumor compared to the ndASC 
group (1,190±517.5 pg/mL), the HdASC group (614.4±209.3 pg/mL), and the non-
treated tumor sample (480.1 pg/mL) (Figure 18).  Similarly, the TGF-β plasma levels in 
the non-treated tumor reached 28,256 pg/mL, versus the HdASC group with 
15,516±1,657 pg/ml, the ndASC group with 20,056±2,083 pg/mL, and the HF20x group 
with 16,673±882.7 pg/mL (Figure 18).  Both one-way ANOVA and t-tests were used in 
order to determine significance between the treatment groups, and no significance was 
observed for either tumor or plasma samples between each of the treatment groups.   
 IFN-γ plays a role in innate and adaptive immunity response against tumors, and 
is predominantly produced by natural killer (NK) cells.  It also plays a role in stimulation 
of natural killer (NK) cell activity, regulation of B-cell functions such as immunoglobulin 
(Ig) production and class switching, and can inhibit melanoma growth through 
regulations of cyclin-dependent kinase mechanisms (Schroder, Hertzog et al. 2004).  
Western blot analysis of IFN-γ demonstrated no treatment-dependent changes in 
homogenized tumor samples within the ndASC group (1.092±0.035), the HF20x group 
(1±0.007), and the HdASC group (0.9235±0.08) (Figure 19).  Both one-way ANOVA 
and T-tests were used in order to determine significance between the treatment groups, 




Figure 19: Determination of IFN-γ Cytokine Response Following Cell-based Therapy.    
A. Western blot membrane showing distinct bands of IFN-γ expression in Non-treated 
(n=1), HF20x (n=3), ndASC (n=3), and HdASC (n=3) tumors. 
B. Graph represents densitometric analysis of IFN-γ staining in A) expressed as fold 
IFN-γ expression.  Samples were normalized to the actin loading control and then 
compared to the HF20x control that was set to 1-fold.   
C. Graph represents the expression levels of IFN-γ (pg/ml) in melanoma tumors of the 
different treatment groups (Non-treated (n=1), HF20x (n=3), ndASC (n=3), and 
HdASC (n=3)) analyzed in triplicates.  One-way ANOVA did not show significant 
differences between the treatment groups (p-value=0.1695), and t-test analysis only 
showed significant changes between the ndASC and HdASC groups (t-test, 
p=0.0228).   
D. Graph represents the expression levels of IFN-γ (pg/ml) within the mouse plasma of 
the different treatment groups (Non-treated (n=1), HF20x (n=3), ndASC (n=3), and 
HdASC (n=3)) analyzed in duplicates.  One-way ANOVA and t-test analysis did not 
show any significance between any of the treatment groups.     
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 The more sensitive ELISA analysis was able to demonstrate a significant decrease 
(t-test p<0.05) in IFN-γ levels in the HdASC group (1.653±0.19 pg/mL) compared to the 
ndASC group (9.492±2.17 pg/mL) suggesting that the hematopoietic differentiated ASC 
might lower IFN-γ cytokine production and thus lower a potential anti-tumorigenic 
immune-responses (Figure 19).  In contrast, the HF20x group (12.04±5.61 pg/mL) had 
the highest levels of IFN-γ present in the tumor, while the non-treated tumor contained 
the lowest levels of IFN-γ (0.8 pg/mL).  The IFN-γ plasma levels did not yield any 
significant differences within the different groups, e.g., the HdASC group (4.496±2.49 
pg/mL), ndASC group (7.754±3.84 pg/mL) and the HF20x group (5.829±1.19 pg/mL), 
and the non-treated tumor (3.408 pg/mL) (Figure 19).  Both one-way ANOVA and t-tests 




 The complex microenvironment of tumors is characterized by a multiple variety 
of cells and signaling factors that are present inside the tumor and around the tumor 
barrier (Bierie and Moses 2006).  Together with the microenvironment, angiogenesis and 
immunogenic responses are the most important contributors regarding mechanisms for 
tumor growth and progression (Kalluri and Zeisberg 2006).  Anti-tumor therapies such as 
genetic engineering of immunogenic cytokine expressing cells or differentiation of 
hematopoietic progenitor cells into immuno-competent cells represent promising 
approaches to eliminate tumor growth.  Correspondingly, the use of immunogenic cell-
based therapies as a treatment option for anti-cancer therapy of melanoma tumors is a 
dynamic field that has the possibility to be very promising (Elzaouk, Moelling et al. 
2006).    
 The success of using cell-based immunotherapies as anti-cancer therapy for 
melanoma is challenged by the complexity of the immune system and potential outcomes 
are relatively unknown.  Accordingly, further studies need to be conducted regarding 
immune system interactions with the microenvironment of the tumor to develop effective 
strategies and treatment plans for multiple types and stages of cancer, including 
melanoma (Blattman and Greenberg 2004; Eggermont and Schadendorf 2009).  This 
study was designed to observe the changes in inflammatory response within the 
melanoma tumor environment through the therapeutic injection of non-differentiated 
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(ndASC) or hematopoietic differentiated ASC (HdASC).  Against the anticipated tumor 
regression following application of our study-based cellular therapies, we observed no 
treatment-dependent tumor regression in the different study groups.  Particularly, the 
group with the highest immunogeneic potential, e.g., HdASC demonstrated a significant 
increased in tumor area expansions and tumor weights suggesting enhanced tumor 
growth and progression of the B16-F1 xenografts in this group compared to the other 
treatment groups.  The enhanced tumor growth following HdASC cell-based therapy was 
further supported by the immunohistochemical analysis of sectioned tumors that 
demonstrated more porous spaced out tumor tissue that also contained an increased 
number of adipose tissue compared to more compact tumors in the HF20x fibroblast 
group.   
 In addition, the tumor growth in the HdASC and the ndASC group was associated 
with increased blood vessel formation compared to lower blood vessel formation within 
the HF20x group.  These data together with the observed decreased expression of the 
tumor specific marker Melan-A within the HdASC group conclude that the observed 
increase in tumor size might result from a combination of the following: inflammatory-
response-related water influx into the tumor area, increased blood vessel formation, or 
formation of a more porous tumor rather than from an actual increase in the proliferation 
of the tumor cells.  These conclusions are also in line with previous studies that analyzed 
thickness of the tumor in correlation with vascularization and demonstrated that larger 
tumors contain an increased amount of blood vessels compared to smaller, more 
contained tumors (Breslow 1970; Kashani-Sabet, Sagebiel et al. 2002; Massi, Franchi et 
al. 2002).  In addition, the observed increase in blood vessels in both the ndASC and 
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HdASC groups versus the HF20x group might be explained with a potential ASC-
dependent secretion of cytokines, pro-angiogenic and anti-apoptotic growth factors 
compared to potential HF20x fibroblast-dependent secretion of the tumor growth factor 
TGF-β.  In detail, previous studies have demonstrated a role of TGF-β-dependent 
fibroblast signaling as prominent modifier in the progression of cancer.  For instance, 
during the early stages of cancer, TGF-β and its signaling pathways can act as a tumor 
suppressor whereas in later stages of cancer development it can act as a pro-carcinogenic 
factor (Reiss 1999; de Caestecker, Piek et al. 2000; Derynck, Akhurst et al. 2001; Kalluri 
and Zeisberg 2006).  Our study demonstrated slight non-significant variations in ELISA 
measured TGF-β levels between the different treatment groups with HF20x having the 
highest TGF-β levels within the tumor tissues.  Accordingly, the fibroblast-dependent 
increase in secretion of the growth factor TGF-β might be one of the factors responsible 
for the initial HF20x treatment-dependent decrease in tumor size at day 2 (Bierie and 
Moses 2006).   
 In contrast, the ASC-dependent release of pro-angiogenic growth factors, e.g., 
vascular endothelial growth factor (VEGF), and hepatocyte growth factor might support 
the formation of blood vessels and endothelial cells within the tumor (Rehman, Traktuev 
et al. 2004; Cao, Sun et al. 2005; Li, Zeng et al. 2006; Locke, Windsor et al. 2009).  
Besides the ASC-dependent release of pro-angiogenic cytokines, the hypoxic conditions 
within the tumor environment might further contribute to the VEGF release from tumor-
originating cells in order to lower the rate of hypoxia-dependent apoptosis by increasing 
endothelial cell formation (Rehman, Traktuev et al. 2004).  Further, recent studies have 
shown that ASC similar bone-marrow derived stem cells (BSC) exposed to or co-cultured 
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with B16-F1 melanoma cells are capable of differentiation into endothelial cell 
phenotypes that also demonstrate expression of tumor angiogenesis promoting growth 
factors VEGF-a, VEGFR-1, VEGFR-2, and Factor VIII (Sun, Sun et al. 2008; Ni, Zhao et 
al. 2009).  The potential of ASC differentiation into tumor endothelial cells is also 
supported by our flow cytometry data that demonstrated appearance of low percentage 
endothelial cell precursor markers (CD34 and 133) within the ndASC group that 
increased during the hematopoietic differentiation of ndASC into HdASC.  In addition, 
histological detection of an actual CFDA-SE stained cell of endothelial cell appearance 
strongly supports the potential of endothelial cell differentiation within the HdASC 
treatment group that might be further supported by the pro-angiogenic environment of the 
tumor itself (Dentelli, Del Sorbo et al. 1999; Zeoli, Dentelli et al. 2008). 
 In opposite to our findings, a recent study demonstrated that specific quantities of 
BSC can help control tumor growth and tumor angiogenesis by induction of endothelial 
cell death and tumor apoptosis (Otsu, Das et al. 2009).  For instance, Otsu et al. 
demonstrated induction of endothelial cell death and apoptosis using co-culture of 
microvascular endothelial cells with BSC within a matrigel matrix-supported capillary 
formation assay.  In addition, the study used B16-F1 cells that were injected into the 
flanks of mice using the capillary formation supporting matrigel matrix.  Thus, major 
study differences between our study and the study by Otsu et al. can be found in tumor 
sizes at the time of cell-based therapy injection and in the total time period of tumor 
growth observation.  For instance, BSC therapy in the study of Otsu et al. was done with 
similar amounts of cells (1x106 cells) that were injected at day 7 of tumor growth when 
tumors had reached 700 mm3 and observation of tumor growth was continued over 11 
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days following the cellular therapy.  In comparison, our study included injection of ASC 
into smaller sized tumors (3 mm diameter) that were observed over a shorter time period 
of 4 days after cellular therapy.  Correspondingly, the observations in our study might 
represent the initial effect of MSC on small size tumors that might change towards 
induction of tumor regression after a longer experimental time period.   
 In contrast to the study by Otsu et al., flow cytometry and histology analysis of 
the different treatment groups revealed small populations of CFDA-SE labeled cells 
growing in small clusters inside and along side of the collected melanoma tumors in all 
treatment groups, e.g. HF20x, ndASC and HdASC with no signs of cell death or 
apoptosis within the CFDA-SE labeled cell populations or the surrounding mouse 
melanoma tissue.  In addition, opposed to the expected host immune response towards 
non-autologous human cell injections, distinct cell morphologies could be observed 
within each of the CFDA-SE labeled human cell populations indicating normal spreading 
and proliferation of the injected cells.  The lack of apoptotic signaling is also supported 
by the lack of changes in caspase-3 detection using Western blotting.  These analysis 
observations rather suggest that the tumor environment allows non-autologous cells of a 
different species to escape the host immune response by promotion of integration into the 
tissue structure for promotion of tumor expansion.  This shows that ASC have the 
potential to reside within the tumor environment without having an effect on tumorigenic 
cell death.  Evidence for this is further supported by studies of Djouad et al. that 
demonstrated BSC-dependent suppression of the general host immune response within 
B16 melanoma and Renca adenocarcinoma by triggering a CD8+ regulatory immune cell 
response for the inhibition of allogeneic lymphocyte proliferation (Djouad, Bony et al. 
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2006; Djouad, Plence et al. 2003).   
 In contrast to the findings by Djouad et al. using non-differentiated BSC, the 
HdASC treatment group in our study demonstrated an up-regulation of macrophage-
marker expressing cells compared to the other treatment groups supporting the existence 
of an immunogenic host response following cellular therapy of hematopoietic-
differentiated ASC.  Thus, the Western detection of changes in macrophage marker 
expressing cells is limited with regards to the human and mouse inter-species reactivity 
of the used antibodies that can only reflect the general immune response of both species 
within the tumor tissue and does not allow any specific conclusions about the mouse-or 
human-specific immunogenic responses.  Correspondingly, appearance of potential ASC 
therapy-induced immunogenic responses are further supported by the Western blotting 
and ELISA observed alterations in expression of the growth inhibitory cytokine IFN-γ 
that is produced predominantly by natural killer (NK) cells as part of the innate anti-
cancer immune response (Ikeda, Old et al. 2002; Kortylewski, Komyod et al. 2004; 
Schroder, Hertzog et al. 2004).  Accordingly, the lowest IFN-γ levels were found in 
tumor and plasma samples of HdASC-treated tumors that resulted in the biggest tumor 
sizes suggesting that the HdASC treatment regimen might have triggered the down-
regulation of the host-derived natural killer cell response.  Thus, our study results indicate 
existence of a macrophage-based immune response following treatment with 
hematopoietic-differentiated cells, the anticipated natural killer cell-dependent host 
immune response following cell-based therapy with induction of IFN-γ was not achieved.   
 We exclude that a potential lack of immunogenicity within the used cell-based 
therapies might play a role in these observations since the preliminary flow-cytometry 
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data analysis supports successful differentiation of the ASCs into hematopoietic immune 
cells.  A potential reason for the observed lack of immunogenicity in the HdASC group 
might be the cell-dose dependency of the host immune response with the experimental 
HdASC cell dose set at a too low concentration.  One potential factor that might play a 
role in interference and efficiency of the tested cell-based therapy of hematopoietic-
differentiated cells might be explained by procedural difficulties during the generation of 
HdASC through growth factors GM-CSF, IL-3, and SCF.  Besides their broad range of 
hematopoietic differentiation potential, these growth factors have pro-angiogenic 
potential and can promote the recruitment and formation of endothelial cells.  
Accordingly, the HdASC differentiation required growth factor SCF in combination with 
the other two growth factors GM-CSF and IL-3 might assist in the formation of mixed 
cell colonies that also contain pro-tumorigenic endothelial cells (Ihle, Keller et al. 1983; 
Migliaccio, Migliaccio et al. 1991; Dentelli, Del Sorbo et al. 1999; Zeoli, Dentelli et al. 
2008).  In addition, residual cytokine contamination of angiogenesis-promoting GM-CSF, 
IL-3 and SCF within the HdASC treatment group might play a role in enhanced blood 
vessel formation, thus, might be negligible due to the stringent washing procedure during 
the harvest and preparation for cell-based therapy.   
 Another reason for the limited immune response seen in our HdASC group might 
be the lack of compatibility between the human and mouse major histocompatibility 
complex (MHC).  Thus, human and mouse MHC show similar the organization, there are 
differences within the genomic regions of the Class I and Class II regions of the complex 
as well as structure of each of the MHC (Yuhki, Beck et al. 2003). These differences in 
genomic regions and according structure of the MHC in humans and mice may provide 
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evidence for the lack of immunogenic responses following HdASC therapy. Thus, the 
connectivity and recognition of the mouse immune system towards the injected HdASC 
may be responsible for the observed limited immune response, and future studies need to 
consider this aspect by analyzing this MHC- dependent immune effect between mouse 
and human MHC Class I or II regions.   
 In summary, this study demonstrated that the hematopoietic differentiation of 
ASCs into HdASCs, using the current procedure, is not able to achieve the desired tumor 
regression.  Even though the preliminary and experimental data show that we were able 
to achieve some level of the hematopoietic differentiation, the generated hematopoietic 
mixed cell population within the HdASC group was not efficient regarding achievement 
of sufficient melanoma tumor regression.  Correspondingly, further work needs to be 
done with focus on selecting the most efficient ASC-derived immunogenic cell 
population for anti-cancer therapy.  For instance, potential experiments should include 
e.g., optimization of the necessary growth factor combination used for differentiation, the 
collection and purification process of the differentiated hematopoietic cells, or the 
determination of the necessary time period to achieve the best hematopoietic 
differentiation of ASCs into HdASCs.  Considering the complex environment of the 
tumor, its ability to incorporate and protect the injected therapeutic cells might further 
challenge potential therapeutic approaches.  Thus, future studies need to include different 
time periods of tumor harvest after cell-based therapy to analyze the potential 
incorporation of the non-host cells into the tumor and their elimination once tumor 




 Some future experiments for the continuation of our experimental idea would 
include:  
1) Establishing and quantifying the effects of the growth factors used for ASC 
differentiation  
2) Further immunohistochemical analysis of the melanoma tumors for determination 
of therapeutic outcome. 
3) To increase the accuracy of tumor area expansion and volume measurements, the 
study needs to include longer tumor growth periods to achieve better measurable 
bigger size initial tumors  
4) Establishing and quantifying cell types associated in the melanoma tumor 
environment  
5) The use of higher animal numbers in order to achieve more statistical significance 
between the treatment groups 
6) Collection of melanoma tumors at different time points to establish growth rates, 
spread, stages, and progression of the melanoma tumors  
7) To analyze the use of potential genetically engineered ndASCs for expression of 
specific cytokine and anti-tumor factors, or toxins (venoms) used singularly or in 
combination with each other in order to help counteract and fight the melanoma 





 Melanoma has become an increasingly important issue today facing many people 
as well as current medicine, and the use of cell-based therapies as treatment options for 
melanoma and other forms of cancer have become a new, upcoming and dynamic field.  
One major aspect of the complex melanoma skin cancer pathology is the release of 
immunosuppressive cytokines from genetically altered melanocytes to obscure tumor 
recognition by the immune system.  Consequently, the direct targeting of immunogenic 
cells to the tumor site might offer a way to eliminate potential tumor escape mechanisms.   
 The objective of this study was to analyze the tissue-specific effect of adipose 
tissue-derived mesenchymal stem cells (ASC) and hematopoietic differentiated ASC 
(HdASC) within a melanoma environment for development of a cell-based anti-cancer 
therapy for melanoma.  Against our expectations, no treatment-dependent tumor 
regression following our cell-based therapies was observed, thus, the group with the 
highest immunogenic potential, for example HdASC, demonstrated an increase in tumor 
growth accompanied with an increased macrophage-based immune response, decreased 
tumor-specific marker Melan-A expression, decreased interferon-γ expression, and 
increased blood vessel formation.  In addition, opposed to the expected mouse host 
immune response towards human cell therapy, histology demonstrated small populations 
of CFDA-SE labeled HF20x, ndASC or HdASC cells inside melanoma tumors with no 
signs of cell death or apoptosis.  The collected data also suggest that the bigger tumor 
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sizes found in presence of HdASC therapy are due to both ASC-supported angiogenesis 
and ASC-dependent induction of a macrophage-based immune cell response with 
according inflammatory water influx resulting in higher tumor porosity rather than 
increased tumor proliferation.  Thus, the tumor environment-dependent integration of 
human species-derived ASC suggests that the generated HdASC may also have a 
suppressive effect on the mouse immune system, so novel therapies that use ASC need to 
focus on ways to raise the host immunogenic effect of ASC all while excluding the 
potential ASC-dependent blood vessel formation within the tumor.   
 The ability of ASC to differentiate along multiple cell lineages makes them ideal 
candidates for use in immuno- or cell-based therapies against melanoma or other types of 
cancer.  Understanding the complexity of the cells or combination of cells in the immune 
response that have the greatest impact in affecting the tumor environment would be 
valuable for the use of ASC in clinical applications of a wide range of cell- and immuno-
based therapies.  Instead of using multiple types of immune cells, selection of a 
specifically differentiated cell may yield the response needed in order to achieve tumor 
regression.  This may be more beneficial when using ASC for injection into a tumor 
environment than having ASC express particular cytokines or anti-cancer agents because 
of the minimal risk of local cytoxicity or decreased expression of the particular ASC 
expressing agent.  The targeted injection of specific differentiated ASC into a melanoma 
tissue environment may be beneficial for future ASC cell-based immunotherapies and 
still remains a novel approach for induction of tumor regression and anticancer therapy in 
melanoma and other cancers.   
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